

International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine

Cephalalgia

2024, Vol. 44(9) 1–31

© International Headache Society 2024

Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/03331024241269735

journals.sagepub.com/home/cep



Francesca Puledra^{1,*}, **Simona Sacco^{2,*}**, **Hans-Christoph Diener³**, **Messoud Ashina^{4,5}**, **Haidar M. Al-Khazali⁴**, **Sait Ashina^{5,6}**, **Rami Burstein⁷**, **Eric Liebler⁸**, **Andrea Cipriani^{9,10,11}**, **Min Kyung Chu¹²**, **Alexandra Cocores¹³**, **Freda Dodd-Glover¹⁴**, **Esme Ekizoglu¹⁵**, **David Garcia-Azorin¹⁶**, **Carl H. Göbel^{17,18}**, **Maria Teresa Goicochea¹⁹**, **Amr Hassan²⁰**, **Koichi Hirata²¹**, **Jan Hoffmann²²**, **Bronwyn Jenkins²³**, **Katharina Kamm²⁴**, **Mi Ji Lee²⁵**, **Yu-Hsiang Ling^{26,27}**, **Marco Lisicki²⁸**, **Daniele Martinelli²⁹**, **Teshamae S. Monteith¹³**, **Raffaele Ornello²**, **Aynur Özge³⁰**, **Mario Fernando Prieto Peres³¹**, **Patricia Pozo-Rosich³²**, **Volodymyr Romanenko³³**, **Todd J. Schwedt³⁴**, **Marcio Nattan P Souza³⁵**, **Tsubasa Takizawa³⁶**, **Gisela M. Terwindt³⁷**, **Janu Thuraiayah⁴**, **Mansoureh Togha^{38,39}**, **Nicolas Vandenbussche^{40,41}**, **Shuu-Jiun Wang^{26,27,42}**, **Shenguan Yu⁴³**, and **Cristina Tassorelli^{29,44}**

¹Headache Group, Wolfson SPaRC, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

²Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy

³Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany

⁴Department of Neurology, Danish Headache Center, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark

⁵Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

⁶Department of Neurology and Department of Anesthesia, Critical Care and Pain Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, USA

⁷Department of Anesthesia, Critical Care and Pain Medicine, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, USA

⁸International Headache Society, London, UK

⁹Department of Psychiatry, University of Oxford, Oxford, UK

¹⁰Oxford Precision Psychiatry Lab, NIHR Oxford Health Biomedical Research Centre, Oxford, UK

¹¹Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK

¹²Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

¹³Department of Neurology-Headache Division, University of Miami, Miller School of Medicine, Miami, USA

¹⁴Department of Medicine and Therapeutics, Korle Bu Teaching Hospital, Accra, Ghana

¹⁵Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

¹⁶Department of Neurology, Hospital Universitario Rio Hortega, University of Valladolid, Valladolid, Spain

¹⁷Kiel Migraine and Headache Centre, Kiel, Germany

¹⁸Department of Neurology, Christian-Albrechts University, Kiel, Germany

¹⁹Neurology Department, Headache Clinic, Fleni, Buenos Aires, Argentina

²⁰Department of Neurology, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt

²¹Neurology, Dokkyo Medical University, Mibu, Tochigi, Japan

²²Wolfson Sensory, Pain and Regeneration Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK

²³Royal North Shore Hospital, St Leonards, Sydney, Australia

²⁴Department of Neurology, Klinikum der Universität München, Munich, Germany

²⁵Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

²⁶Neurological Institute, Taipei Veterans General Hospital, Taipei

²⁷College of Medicine, National Yang Ming Chiao Tung University, Taipei

²⁸Instituto de Investigación Médica Mercedes y Martín Ferreyra (INIMEC), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Universidad Nacional de Córdoba, Córdoba, Argentina

²⁹IRCCS Mondino Foundation, Headache Science and Rehabilitation Unit, Pavia, Italy

³⁰Department of Neurology, Mersin University School of Medicine, Mersin, Turkey

³¹Institute of Psychiatry, HCFMUSP, Sao Paulo, Brazil

³²Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron & Headache & Neurological Pain Research Group, Vall d'Hebron Institute of Research, Barcelona, Spain

³³Vita Medical Center, Kyiv, Ukraine

³⁴Department of Neurology, Mayo Clinic, Phoenix, USA

³⁵Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil

³⁶Department of Neurology, Keio University School of Medicine, Tokyo, Japan

³⁷Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands

³⁸Neurology ward, Sina Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

³⁹Headache department, Iranian Center of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

⁴⁰Department of Neurology, Ghent University Hospital, Ghent, Belgium

⁴¹Department of Neurology, AZ Sint-Jan Brugge, Bruges, Belgium

⁴²Brain Research Center, National Yang Ming Chiao Tung University, Taipei



Keywords

International Headache Society, migraine, practice recommendations, preventative treatments

Date received: 3 May 2024; revised: 24 June 2024; accepted: 24 June 2024

Introduction

Consistent with the mission of the International Headache Society (IHS) to improve migraine management worldwide, this document focuses on providing practical recommendations on the preventive pharmacological management of migraine. Due to the inconsistent availability of medications across different regions of the globe, these recommendations are categorized into two levels: Optimal and Essential. The Optimal level is intended for settings where most drug treatments are available. The Essential level is focused on countries where only the drugs listed in the World Health Organization (WHO) Model List of Essential Medicines (EML) are available (1).

In this second part of the IHS endeavor, we present the recommendations for the preventive pharmacological treatment of migraine together with the methodology and the evidence used to support them. Table 1 lists the drugs with evidence of efficacy for the preventive treatment of migraine listed in the WHO EML.

The IHS practice recommendations are based on available treatment guidelines and expert consensus. They are intended to be a practical, quick reference, applicable in all countries across different care settings, including primary care. Given the global scope of these recommendations we have not customized the recommendations based on national registrations or specific labelling in individual countries. Nothing in these guidelines is designed to supersede local labelling and approvals.

These recommendations represent an instrument to motivate and facilitate policy changes. Our goal is to establish essential standards of migraine management in as many countries as possible. These standards will also serve as a reference document to drive local advances toward optimal care once essential standards of care are met.

Methodology used for the development of questions and recommendations

The methodology was similar to the one used for the IHS Practice Recommendations for the pharmacological acute treatment of migraine (2). The working group panel was

nominated by the IHS board, selecting members based on their specific expertise in different areas of headache, previous experience developing guidelines or recommendations, and representation of different regions of the world. The group was gender-balanced and professional backgrounds included neurology, methodological expertise, evidence synthesis and statistics. Each senior member worked in collaboration with two junior headache experts from a different geographic origin for the analysis of the literature and the explanation of the recommendations. AC was specifically involved for his expertise in the methodology of evidence-based synthesis.

We used a consensus development panel approach, adapted from the methodology described and used by the US National Institutes of Health and WHO (3). The Steering Committee (HCD, MA, CT) developed an initial set of clinical questions in the Spring of 2022 based on the main issues that healthcare professionals may encounter in everyday practice when treating persons with migraine. The initial list of clinical questions was first shared and discussed with the coordinators (SS and FP) and, subsequently, with the entire working group (seniors and juniors) for interactive discussion and optimization. Following several iterations, the final set of clinical questions was agreed in the Fall of 2022.

AC devised and performed the search of the published literature to identify the National and International Guidelines for migraine treatment to be used for elaborating the recommendations. Considering the very specific questions and the relatively small amount of records overall for preventive treatment, AC ran and combined two searches: Search 1 (“Migraine Disorders” [MeSH Terms]) AND (“Secondary prevention” [MeSH Terms]) and Search 2 (“Therapeutics” [Mesh]) AND (“Migraine Disorders” [Mesh]) AND (prevention OR prophylaxis)).

The following filters were applied to the searches: “Consensus Development Conference”, “Guideline”, “Guidelines”, “Meta-Analysis”, “NIH”, “Practice Guideline”, “Review”, “Systematic Review”.

FP and SS assessed the search output and selected a total of 15 national/international guidelines and

⁴³Department of Neurology, Chinese PLA General Hospital, Beijing, China

⁴⁴Department of Brain and Behavioral Science, University of Pavia, Pavia, Italy

*Francesca Puledda and Simona Sacco equally contributed.

Corresponding author:

Cristina Tassorelli, IRCCS Mondino Foundation, Headache Science and Rehabilitation Unit, Via Mondino 2, 27100 Pavia, Italy.
Email: cristina.tassorelli@unipv.it

Table 1. Drugs recommended for the preventive treatment of migraine by international guidelines, and their availability in the WHO model list of essential medicines, 23rd list (2023) (1).

	On EML for migraine	On EML for other uses	Available formulation and dose on EML	Recommended formulation and dose
Antiepileptics				
Valproic acid*	No	Yes	Oral liquid: 200 mg/5 mL; Tablet (crushable): 100 mg; Tablet (enteric-coated): 200 mg, 500 mg; Injection: 100 mg/mL in 3 mL, 4 mL, 10 mL ampoule	Oral 400–2000 mg /day
Topiramate*	No	No		Oral 25–200 mg /day
Lamotrigine	No	Yes	Tablet: 25 mg, 50 mg, 100 mg, 200 mg; Tablet (chewable, dispersible): 2 mg, 5 mg, 25 mg, 50 mg, 100 mg, 200 mg	Oral 25–200 mg /day
Beta-blockers				
Metoprolol	No	No		Oral 25–200 mg /day
Propranolol	Yes	—	Tablet: 20 mg, 40 mg (hydrochloride).	Oral 120–240 mg /day
Atenolol	No	No		Oral 50–200 mg /day
Bisoprolol	No	Yes	Tablet: 1.25 mg; 5 mg	Oral 5 mg /day
Timolol	No	No		Oral 10–60 mg /day
Nadolol	No	No		Oral 40–160 mg /day
Angiotensin Receptor Blockers/ACE inhibitors				
Candesartan	No	No		Oral 8–16 mg /day
Lisinopril	No	No		Oral 10–20 mg /day
Calcium Channel Blockers				
Flunarizine	No	No		Oral 5–10 mg /day
Serotonin antagonists				
Pizotifen	No	No		Oral 0.5–4.5 mg /day
Antidepressants				
Amitriptyline	No	Yes	Tablet: 10 mg, 25 mg, 75 mg	Oral 25–150 mg /day
Venlafaxine	No	No		Oral 37.5–300 mg /day
Monoclonal antibodies targeting the CGRP pathway				
Erenumab	No	No		Subcutaneous injection 70–140 mg monthly
Fremanezumab	No	No		Subcutaneous injection 225 mg monthly, 675 mg quarterly
Galcanezumab	No	No		Subcutaneous injection of 240 mg as a loading dose, followed by 120 mg monthly
Eptinezumab	No	No		Intravenous infusion 100–300 mg quarterly Intramuscular injections 155–195 U quarterly
OnabotulinumtoxinA				
Local anesthetics				
Lidocaine	No	Yes	Injection: 1%; 2% (hydrochloride) in vial	Local intramuscular injection 1–2%
Bupivacaine	No	Yes	Injection: 0.25%; 0.5% (hydrochloride) in vial	Local intramuscular injection 0.5%
Steroids				
Methylprednisolone	No	Yes	Injection: 40 mg/mL (as sodium succinate) in 1 mL single-dose vial and 5 mL multi-dose vials; 80 mg/mL (as sodium succinate) in 1 mL single-dose vial	Local intramuscular injection 40–80 mg
Dexamethasone	No	Yes	Injection: 4 mg/mL (as disodium phosphate salt) in 1 mL ampoule; Oral liquid: 2 mg/5 mL; Tablet: 2 mg, 4 mg.	Intravenous infusion or intramuscular injection 4–8 mg

(continued)

Table 1. (continued)

	On EML for migraine	On EML for other uses	Available formulation and dose on EML	Recommended formulation and dose
Gepants				
Atogepant	No	No		Oral 10, 30 twice daily or 60 mg daily
Rimegepant	No	No		Oral (dispersible tablet) 75 mg every other day

*According to the European Medicines Agency these drugs must be avoided during pregnancy and in women of childbearing age who are not using highly effective contraception.

guidance documents for elaborating the recommendations, based on: i) relevance of the paper; ii) publication date of less than 15 years prior; iii) availability in the English language. A further three guidelines (from German, Korean and Taiwanese societies) were added subsequently following either a translation to English being made available or internal suggestions coming directly from the working group ([Online Supplemental file #1](#)) (4–21). In the kick-off meeting held virtually in February 2023, each triad of experts, formed by a senior and two juniors, undertook the task to elaborate a first draft of recommendations for 2–3 clinical questions. Once all the triads had elaborated the assigned recommendations, these were shared with the entire working group for discussion and refinement. Several runs of discussion via virtual meetings or e-mail exchanges led to the final version agreed by all the components in December 2023.

The final list of clinical questions and the corresponding recommendations are summarized in Table 2.

In the next sections we will illustrate in detail each clinical question, associated recommendations for the Optimal and Essential level, background for the question and evidence used for the elaboration.

Q1 – Which individuals with migraine are candidates for preventive pharmacologic treatment?

Recommendations

Optimal.

We suggest starting a migraine preventive treatment with drugs when one or more of the following conditions is present:

- the person has 4 or more monthly headache days;
- migraine has an impact on personal, social, and professional life according to personal patient perception;
- optimized acute treatment is ineffective in providing migraine relief;

- acute medications are used frequently to treat the attacks.

Essential.

As described in the optimal recommendations.

Comment: Due to the debilitating nature of migraine attacks and the potential risk of negative sequelae, preventive treatment can be considered with a lower threshold of monthly headache days in people with migraine with aura, especially hemiplegic migraine and migraine with prolonged aura.

Background. Migraine is a multifactorial disorder with a significant impact on patients' lives. The prevalence of migraine is the highest between 20 and 50 years of age, but people of all ages are affected (22). According to the latest assessment of the Global Burden of Disease, migraine is the first leading cause of disability due to a disorder of the nervous system worldwide in older children and adolescents aged 5–19 years and the second in people aged 20–59 years (23). Women are three times more affected than men (22). One of the pillars of treatment consists of preventive therapies to reduce the negative impact of migraine on everyday life by reducing the frequency of days with migraine. There are several different medication classes available for migraine prevention (e.g., anti-hypertensive, anti-epileptic, anti-depressant, treatments targeting the calcitonin gene-related peptide pathway). The decision to start a preventive migraine medication should take into consideration several factors, including frequency, severity, duration of migraine attacks, presence of other headaches (e.g. tension-type headache), magnitude of the impact that the migraine attacks have on daily functioning, effectiveness of acute medication, frequency of administration, and patient preference (24).

Evidence. Multiple headache expert groups and organizations have developed guidelines that provide recommendations on when preventive treatments should be considered for persons with migraine (summarized in [Online Supplemental Table 1](#)).

These guidelines consistently suggest that migraine frequency and migraine-associated disability are important factors when deciding to offer migraine preventive treatment

Table 2. Summary table illustrating the clinical questions for the pharmacological preventive treatment of migraine and the corresponding optimal and essential level recommendations.

Question Number	Optimal level	Essential Level
1 – Which individuals with migraine are candidates for preventive pharmacologic treatment?	We suggest starting a migraine preventive treatment with drugs when one or more of the following conditions is present: - the person has four or more monthly headache days; - migraine has an impact on personal, social, and professional life according to personal patient perception; - optimized acute treatment is ineffective in providing migraine relief; - acute medications are used frequently to treat the attacks.	As described in the recommendations for the optimal level.
2 – When should the effectiveness of a migraine preventive treatment be assessed?	In individuals initiating a new migraine oral preventive treatment, we suggest evaluating effectiveness after three months at the target dose. We recommend a minimum of three months for injectable drugs taken on a monthly basis, and a minimum of six months for injectable drugs administered quarterly.	In individuals initiating a new oral preventive treatment, we suggest evaluating effectiveness after three months of treatment at target dose.
3 – If an initial migraine preventive drug is ineffective or not well tolerated, should alternative drug options be considered?	If an initial migraine preventive drug is ineffective or not well tolerated, we suggest switching to a different class of medication. In individuals with multiple drug failures, a further option may be switching to a different preventive treatment in the same therapeutic class or to drugs such as onabotulinumtoxinA, monoclonal antibodies targeting CGRP and gepants, which have demonstrated efficacy in individuals who did not benefit from multiple previous preventive treatments.	If an initial migraine preventive drug is ineffective or not well tolerated, we suggest switching to a different class. In individuals with multiple drug failures, a further option may be switching to a different preventive treatment in the same class.
4 – If a migraine preventive drug is ineffective, is it appropriate to use a combination therapy with two migraine preventive drugs?	We suggest combination therapy with two migraine preventive agents in individuals who do not have enough benefit from any single migraine preventive treatment, or if the combination of two agents represents an advantage on the management of comorbidities. Drugs targeting the CGRP pathway and onabotulinumtoxinA have very low/absent drug-to-drug interactions and they can therefore be easily combined with oral preventive treatment.	We suggest a combination therapy with two migraine preventive agents in individuals who do not have enough benefit from any single migraine preventive treatment, or if the combination of two agents represents an advantage on the management of comorbidities. Oral preventive treatments have several drug-to-drug interactions, therefore caution is suggested when combining them. On the other hand, some combinations may improve the tolerability of individual drugs.
5 – How long should effective migraine prevention be continued?	An effective preventive treatment should be continued for at least six months for oral drugs and 12 months for non-oral treatments before considering discontinuation. For people with chronic migraine, longer treatment periods should be considered. The decision to stop a migraine preventive drug should be based on having less than four monthly migraine days over a period of	An effective preventive treatment with available oral drugs should be continued for at least six months. For chronic migraine longer treatment periods should be considered. The decision to stop a migraine preventive drug should be based on having less than four monthly migraine days over a period of three consecutive months or based on the

(continued)

Table 2. (continued)

Question Number	Optimal level	Essential Level
6 – What are the success criteria to rate preventive therapy as effective?	three consecutive months or based on the patient's satisfaction with the reduction of disease burden achieved. The success criteria that determine whether preventive therapy is effective and should be continued according to the recommendations provided in Q5 are any one or more of the following: - a $\geq 50\%$ decrease in monthly migraine days or moderate-to-severe headache days, optimally based on the use of a headache diary; - a clinically meaningful subjective improvement as reported by the subject or evaluated by Patient Global Impression scales; - a clinically meaningful improvement in MIDAS or HIT-6 questionnaire scores. For subjects with chronic migraine who have not achieved a $\geq 50\%$ decrease in monthly migraine days or moderate-to-severe headache days with multiple preventive options (including oral drugs, onabotulinumtoxinA and drugs targeting the CGRP pathway), a $\geq 30\%$ decrease in monthly migraine days or moderate-to-severe headache days is acceptable for treatment continuation beyond three months.	patient's satisfaction with the reduction of disease burden achieved. Given the limited number of options available, it is recommended to continue treatment in all subjects that report a meaningful subjective improvement and who do not have tolerability issues or unwanted side effects.
7 – In individuals who have discontinued a migraine preventive after a successful period, what are the criteria for restarting preventive treatment?	In individuals who have discontinued migraine prevention after a successful period of treatment, we suggest waiting at least one month before considering restarting treatment, provided they still satisfy the criteria for prevention (refer to Q1). Monitoring of headache frequency with a headache diary or a monthly calendar is recommended after stopping a migraine preventive treatment.	As described in the optimal recommendations.
8 – Should the choice of migraine preventive drugs be determined by the presence of comorbidities?	The first treatment option should always be a migraine-specific drug. In individuals with migraine and an ongoing comorbid condition, it is possible to use agents that can provide benefit on both the migraine and the existing comorbidity. This applies specifically to oral preventive treatments (see Table 4).	When migraine-specific treatments are not available, the choice of oral preventive treatment should be guided by the presence of comorbidities. We therefore suggest using agents that can provide benefit on both migraine and the existing comorbidity as first line preventive therapy.
9 – Which preventive medication is suggested for people with chronic migraine?	We suggest atogepant, erenumab, eptinezumab, fremanezumab, galcanezumab, onabotulinumtoxinA and topiramate for people with chronic migraine. Of note, topiramate should be avoided during pregnancy and in women of childbearing age who are not using highly effective contraception methods.	We suggest topiramate, which however must be avoided during pregnancy and in women of childbearing age who are not using highly effective contraception methods. If topiramate is not effective, not tolerated or not indicated, amitriptyline, beta-blockers, valproate can be used. Combination of two drugs may be

(continued)

Table 2. (continued)

Question Number	Optimal level	Essential Level
I0 – If a monoclonal antibody targeting the CGRP pathway is not effective, is it beneficial to switch to another anti-CGRP monoclonal antibody?	If a monoclonal antibody targeting the CGRP pathway (anti-CGRP mAb) is ineffective, we suggest switching to another anti-CGRP mAb in individuals who have no other viable therapeutic options among other migraine preventive drug classes due to ineffectiveness, contraindications or tolerability issues.	necessary, following recommendations provided in Q4. Not applicable.
I1 – What are the possible preventive options for people with migraine who have a positive response to a monoclonal antibody targeting the CGRP pathway, but still have a clinically meaningful residual migraine burden?	In people with migraine who have a positive response to one monoclonal antibody targeting CGRP but still have a clinically meaningful residual migraine burden, we suggest adding a traditional oral preventive drug or, if the person has chronic migraine, onabotulinumtoxinA.	Not applicable.
I2 – Do greater occipital nerve blocks have a place in migraine prevention?	Greater occipital nerve blocks with local anesthetics, with or without corticosteroids, have limited evidence of efficacy, but may represent an option for migraine prevention. They can also be used in pregnant women.	As described in the optimal recommendations.
I3 – What are the suggested drugs for migraine prevention in children and adolescents?	In children and adolescents with migraine who need pharmacological migraine prevention, beta-blockers or flunarizine, at doses adapted to body weight, can be used, although evidence of efficacy is very limited. In case of ineffectiveness, low dose topiramate or amitriptyline represent possible alternatives.	In children and adolescents with migraine who need pharmacologic migraine prevention, beta-blockers, at doses adapted to body weight, can be used, although evidence of efficacy is very limited. In case of ineffectiveness, low dose topiramate or amitriptyline represent possible alternatives.
I4 – Which migraine preventive drugs can be used during pregnancy and lactation?	<u>Pregnancy</u> We suggest non-pharmacologic treatments or peripheral nerve blocks (see Q12) as first line options in pregnant or breastfeeding women. If non-pharmacological treatment is not possible or effective, we suggest propranolol or amitriptyline, after balancing risks and benefits and informing the person on potential secondary effects and associated risks. Propranolol should be discontinued in the last part of the third trimester to avoid the risk of adverse events to the fetus and neonate. For women with chronic migraine, onabotulinumtoxinA, may represent an option after balancing risks and benefits given the limited systemic effects. We strongly recommend avoiding valproate and topiramate during pregnancy due to their teratogenic effects. Similarly, candesartan and lisinopril should be avoided during pregnancy because of the risk of harm and malformation to the fetus. <u>Breastfeeding</u> During breastfeeding, non	<u>Pregnancy</u> We suggest non-pharmacologic treatments or peripheral nerve blocks (see Q12) as first line options in pregnant or breastfeeding women. If non-pharmacological treatment is not possible or effective, we suggest propranolol or amitriptyline, after balancing risks and benefits and informing the patient on potential secondary effects and associated risks, we suggest propranolol or amitriptyline, after balancing risks and benefits and informing the individual on potential secondary effects and associated risks. Propranolol should be discontinued in the last part of the third trimester to avoid the risk of adverse events to the fetus and neonate. We strongly recommend avoiding valproate and topiramate during pregnancy due to their teratogenic effects. <u>Breastfeeding</u> Non pharmacologic treatment or peripheral nerve blocks should be considered first line. If non-pharmacological treatment is not possible or effective, we suggest

(continued)

Table 2. (continued)

Question Number	Optimal level	Essential Level
	pharmacologic treatment or peripheral nerve blocks should be considered first line. If non-pharmacologic treatment is not possible or effective, we suggest propranolol or amitriptyline, after informing the individuals of the potential secondary effects and associated risks, or onabotulinumtoxinA for people with chronic migraine. Candesartan can be used with caution. Lisinopril should be avoided. Monoclonal antibodies targeting CGRP can be used with caution after at least two weeks postpartum.	propranolol or amitriptyline, after informing the individuals of potential secondary effects and associated risks.
I5 – Which migraine preventive drugs can be used in people with migraine over 65 years of age?	We suggest selecting the drug for migraine prevention in people with migraine over 65 years after considering possible comorbidities and the needs of dose adjustments, for all treatments. We suggest careful clinical monitoring to allow for early detection of adverse effects, as well as the potential need to modify the course of treatment. Some drugs targeting the CGRP pathway have been tested in populations up to 80 years old without safety issues and can therefore represent an option. For people with chronic migraine, onabotulinumtoxinA may represent an option given the limited, if any, systemic effect.	We suggest selecting the drug for migraine prevention in people with migraine over 65 years after considering possible comorbidities and the needs of dose adjustments, for all treatments. We suggest careful clinical monitoring to allow for early detection of adverse effects, as well as the potential need to modify the course of treatment.
I6 – What is the recommended approach to people with migraine and medication overuse?	In people with migraine and medication overuse the following approaches are recommended: - reduced intake of overused drug(s) simultaneous with the initiation of preventive treatment; - reduced intake of overused drug(s) followed by initiation of preventive treatment; - interruption of overused drug(s) followed by initiation of preventive treatment. The selection of the preventive treatment must be based on evidence of therapeutic efficacy, patient history and comorbidities. Monoclonal antibodies targeting the CGRP pathway, topiramate and onabotulinumtoxinA have proven effective regardless of the presence of medication overuse, therefore the immediate withdrawal or reduction of the overused drug might not be necessary in subjects who are initiating such a treatment. Individuals overusing opioids or barbiturate containing drugs may require hospitalization to manage drug discontinuation safely and successfully.	In people with migraine and medication overuse the following approaches are recommended: - reduced intake of overused drug(s) simultaneous with the initiation of preventive treatment; - reduced intake of overused drug(s) followed by initiation of preventive treatment; - abrupt interruption of overused drug(s) followed by initiation of preventive treatment. The selection of the preventive treatment must be based on evidence of therapeutic efficacy, patient history and comorbidities. Topiramate has proven effective regardless of the presence of medication overuse, therefore the immediate withdrawal or reduction of the overused drug might not be necessary in subjects who are initiating such a treatment. Individuals overusing opioids or barbiturate containing drugs may require careful monitoring to manage drug discontinuation safely and successfully.

with drugs. Most guidelines propose that migraine preventive medications should be offered if there is a minimum of two to four days with migraine per month. This is especially true if the migraine attacks cause disability and are not quickly responsive to acute migraine medications. People with migraine with attacks associated with prolonged and/or severe auras may be offered migraine preventive medications, regardless of attack frequency. If acute migraine treatment is not effective or the subject has contraindication to their use, preventive treatment should be offered. All people with migraine overusing acute medications, as well as those who are at risk of medication overuse should be offered preventive treatment. Other indicators for initiating preventive treatment are absences from work or school due to migraine and substantial negative impact on daily routines.

The decision to initiate preventive treatment must be made in agreement with the patient, adopting a personalized and shared decision-making process. Potential benefits, side effects, and risks associated with the use of preventive medications should be discussed and carefully considered. This discussion and decision-making process should include patient-specific factors such as age, child-bearing potential, presence of other health conditions, potential for medication interactions, and ability to adhere to the medication dosing schedule, amongst others.

Q2 – When should the effectiveness of a migraine preventive treatment be assessed?

Recommendations

Optimal.

In individuals initiating a new migraine oral preventive treatment, we suggest evaluating effectiveness* after three months at the target dose. We recommend a minimum of three months for injectable drugs taken on a monthly basis, and a minimum of six months for injectable drugs administered quarterly.

Essential.

In individuals initiating a new oral preventive treatment, we suggest evaluating effectiveness* after three months of treatment at target dose.

**See Q6 for the criteria for assessing the effectiveness of a preventive therapy.*

Comment: Some evidence suggests that a small percentage of persons with chronic migraine treated with onabotulinumtoxinA may become responders at later times (after the second or third cycle). In non-responders to onabotulinumtoxinA after the first cycle, the dose should be increased from 155 U to 195 U in the subsequent cycle (25,26).

Background. The number of weeks needed for a preventive treatment to show maximum efficacy varies between drugs and subjects and may require several weeks. In contrast, adverse effects typically occur early. In the case of oral treatments, adverse effects may be minimized with a gradual titration.

Evidence. Preventive medication may show a rapid onset of benefit. This can occur within a week in the case of onabotulinumtoxinA, erenumab, galcanezumab, fremanezumab, eptinezumab and atogepant; or even within a few hours as described for eptinezumab and for rimegepant that has proven effective in the acute treatment of migraine also (27–35). However, most drugs require a minimum of four to six weeks after reaching the therapeutic dose to show their maximum therapeutic benefit (29–37). In addition, efficacy might be dose dependent, especially for traditional oral preventive drugs. In case of insufficient efficacy but good tolerability, the dose of these can be increased until the maximum tolerated or recommended dose (36–39).

Oral preventive treatment should be started and titrated progressively, to minimize adverse effects. Progressive titration of the selected drug may decrease the probability of adverse effects, and some adverse symptoms may dissipate after a few days of use (34–37). Many treatment-emergent adverse effects are drug-specific, and typically present early in treatment (40–43).

The response to preventive medications is highly heterogeneous among the migraine population. In addition, migraine is a cyclic and fluctuating disease, and the frequency of migraine attacks changes depending on several different factors (44). There is no consensus on the optimal time point to judge treatment efficacy, however, most randomized controlled trials (RCTs) and real-world studies assess the efficacy after three months of use, with some exceptions. Most recent guidelines recommend a minimum treatment duration of 4–12 weeks (Online Supplemental Table 2). A delayed response has been reported in some cases, however, and needs to be considered (45,46).

Q3 – If an initial migraine preventive drug is ineffective or not well tolerated, should alternative drug options be considered?

Recommendations

Optimal.

If an initial migraine preventive drug is ineffective* or not well tolerated, we suggest switching to a different class of medication. In individuals with multiple drug failures, a further option may be switching to a different preventive treatment in the same therapeutic class or to drugs such as onabotulinumtoxinA, monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) and gepants, which have

demonstrated efficacy in individuals who did not benefit from multiple previous preventive treatments.

Essential.

If an initial migraine preventive drug is ineffective* or not well tolerated, we suggest switching to a different class. In individuals with multiple drug failures, a further option may be switching to a different preventive treatment in the same class.

**Less than 30% reduction in monthly migraine days or moderate-to-severe headache days or rated as such by the person with migraine after an appropriate period of time (see Q2) at adequate doses.*

Background. Migraine preventive drugs have a broad range of efficacy and side effects. In some cases, an initial preventive drug is ineffective or not tolerated, and therefore must be terminated. When it is determined that a migraine preventive medication is ineffective, or if it is not tolerated, switching to another migraine preventive medication is a reasonable next step (15,18,19).

Evidence. There is strong evidence that compliance with oral migraine preventive medications is low, mostly due to lack of long-term efficacy and side effects. A 2017 retrospective analysis in the US revealed that only 25% of people with chronic migraine who started a preventive drug persisted with the treatment after six months (45). Among participants who discontinued, 23% switched to another preventive drug. Pooled persistence from 19 RCTs on propranolol, amitriptyline, and topiramate showed rates of 77%, 55%, and 57%, respectively, at 16–26 weeks (47). Adverse events were the most common reason for discontinuation.

There is a lack of studies that have directly investigated the methods for switching migraine preventive medications and the related outcomes. There are several recently completed clinical trials, however, demonstrating that people with migraine who have not responded to or not tolerated prior migraine preventive medications can respond to other pharmacologic options. The monoclonal antibodies targeting the calcitonin gene-related pathway (anti-CGRP mAbs), for example, have been studied for the treatment of both episodic and chronic migraine in participants who had failed previous preventive treatment (48–50). OnabotulinumtoxinA has demonstrated efficacy in people with chronic migraine and prior preventive treatment failures (51–53).

Most guidelines suggest switching preventive treatments in case of ineffectiveness after an adequate trial, although the length of ‘adequate’ may vary, and periodic re-evaluation is recommended. Online Supplemental Table 3 summarizes guidance on the timing for assessing outcomes with migraine preventive medications and switching such medications reported in the guidelines and guidance documents assessed.

Q4 – If a migraine preventive drug is ineffective, is it appropriate to use a combination therapy with two migraine preventive drugs?

Recommendations

Optimal.

We suggest combination therapy with two migraine preventive agents in individuals who do not have enough benefit from any single migraine preventive treatment, or if the combination of two agents represents an advantage on the management of comorbidities.

Drugs targeting the CGRP pathway and onabotulinumtoxinA have very low/absent drug-to-drug interactions and they can therefore be easily combined with oral preventive treatment.

Essential.

We suggest a combination therapy with two migraine preventive agents in individuals who do not have enough benefit from any single migraine preventive treatment, or if the combination of two agents represents an advantage on the management of comorbidities.

Oral preventive treatments have several drug-to-drug interactions, therefore caution is suggested when combining them. On the other hand, some combinations may improve the tolerability of individual drugs.

Background. Preventive migraine options consist of several evidence-based pharmaceutical interventions as well as nonpharmacologic treatments including lifestyle changes and behavioral approaches.

Recommended migraine preventives include beta-blockers, topiramate, valproate, flunarizine, amitriptyline and angiotensin receptor blockers, as well as newer migraine specific anti-CGRP mAbs and gepants. Injections with onabotulinumtoxinA are also approved in several countries, albeit for chronic migraine only. Effectiveness of drug prophylaxis is generally defined as a 50% reduction in monthly migraine days in episodic migraine and 30% for chronic migraine. Drug prophylaxis is sometimes not (or only partially) effective, and adherence may be limited by tolerability.

Evidence. No formal evidence exists, in the form of controlled studies, for combination therapy of two preventives (54). In one study, the specific combination of topiramate and propranolol did not provide additional benefits compared to the use of topiramate alone or placebo (55). Similarly, the use of combined tricyclic antidepressant and propranolol was no better than propranolol monotherapy (54). The combination of propranolol with nortriptyline did not provide

Table 3. Possible combinations of preventive drugs for migraine based on mechanisms of action of the drugs or their drug-to-drug interaction profile.

Drug classes	Drugs	
Beta-blockers + anticonvulsants	Propranolol + divalproex sodium; propranolol + topiramate	Limited evidence is available. The classes have a different mechanism of action. Beta-blockers have limited side effects, although their chronic intake may worsen an existing depression
Beta-blockers + tricyclic antidepressants	Propranolol + nortriptyline Propranolol + amitriptyline	No reliable evidence is available, but the two classes have a different mechanism of action and tricyclic antidepressant may prevent/improve depression
Anticonvulsants + tricyclic antidepressants	Topiramate + nortriptyline or amitriptyline	Evidence of efficacy is lacking although a small randomized controlled trial suggests the safety of the combination of propranolol with nortriptyline. Sedation may worsen with the use of both drugs, but topiramate may counteract amitriptyline-induced weight gain
CGRP targeting monoclonal antibodies + botulinum toxins	Erenumab, galcanezumab or fremanezumab + onabotulinumtoxinA	Preclinical and clinical data suggest potential for synergy due to distinct mechanisms of action. Multiple small studies have shown a greater reduction in mean headache/migraine days with this combination (57–59). The two classes have limited drug-to-drug interaction
CGRP targeting monoclonal antibodies + gepants	Galcanezumab + rimegepant	The two classes have a shared mechanisms of action, which may therefore potentiate the effect, but evidence of efficacy and safety is needed
CGRP targeting monoclonal antibodies + oral migraine preventive medications	Erenumab + topiramate; fremanezumab + propranolol	The classes have a different mechanism of action and CGRP targeting monoclonal antibodies have a proven good tolerability profile without central side effects
CGRP receptor inhibitors + oral migraine preventive medications	Rimegepant or atogepant + topiramate or propranolol or amitriptyline	The classes have a different mechanism of action and CGRP antagonists have a proven good tolerability profile without central side effects
Other possible combinations		
Preventive drugs and biobehavioral therapy		
Non-invasive neurostimulation device and preventive drugs		

CGRP: calcitonin gene-related peptide.

better results than propranolol alone (56). Anecdotal evidence exists that the addition of anti-CGRP mAbs to onabotulinumtoxinA may lead to a further reduction in headache frequency in some persons with chronic migraine (57–59). An open trial showed that combining a beta-blocker and sodium valproate could lead to an advantage in efficacy in participants with migraine previously resistant to the two medications in monotherapy (60). Similar benefits were found for combining beta-blocker and topiramate (59) as well as topiramate and nortriptyline (61) in individuals resistant to both respective monotherapies. Examples of viable combinations with preventive drugs for migraine are provided in Table 3.

We suggest monotherapy as a goal in addition to lifestyle modification and other non-medical therapies when possible. In cases of partial (or no) effectiveness, the adherence to treatment, adequate trial of at least eight weeks at the target dose, and any potential medication overuse should be reviewed. In people with migraine with unmet needs

despite monotherapy plus lifestyle changes and behavioral support, combinations can be considered. To select the drugs to be combined it is necessary to consider the individual patient, their medical and other co-morbidities, personal preferences, side effect profiles, and route of administration.

The statements on the combination of two preventives reported in the guidelines reviewed and the guidance documents assessed are summarized in Online Supplemental Table 4.

Q5 – How long should effective migraine prevention be continued?

Recommendations

Optimal.

An effective preventive treatment should be continued for at least six months for oral drugs and 12 months for non-oral treatments before considering discontinuation. For people

with chronic migraine, longer treatment periods should be considered.

The decision to stop a migraine preventive drug should be based on having less than four monthly migraine days over a period of three consecutive months or based on the patient's satisfaction with the reduction of disease burden achieved.

Essential.

An effective preventive treatment with available oral drugs should be continued for at least six months. For chronic migraine longer treatment periods should be considered.

The decision to stop a migraine preventive drug should be based on having less than four monthly migraine days over a period of three consecutive months or based on the patient's satisfaction with the reduction of disease burden achieved.

Background. Several drugs have shown efficacy in the preventive treatment of migraine. Most randomized clinical trials evaluate the efficacy of preventive medications after three to six months. The IHS Guidelines for controlled trials of preventive treatment of chronic and episodic migraine suggest the use of a double-blind treatment phase lasting at least 12 weeks (62,63). These Guidelines suggest that trials of 24 weeks or longer may be useful in evaluating cumulative benefit, persistence of efficacy, adherence to treatment, safety, and tolerability.

Evidence. Most RCTs and real-world evidence studies (RWE) evaluated the efficacy of treatment after three or six months (64–66). Some open-label studies and a few RCTs reported the persistent effectiveness of some treatments over longer treatment periods (51,67–70). Based on this evidence, most guidelines recommend the use of preventive treatments for 6–12 months (Online Supplemental Table 5) (71,72).

The vast majority of RCTs and RWE studies focused on the effect of the treatment on migraine during the treatment phase, however, and information regarding the discontinuation phase is limited. This post-treatment period observation would be highly beneficial in order to identify possible rebound phenomena, but this is not always evaluated or reported in the clinical trials (62,63).

To date, one double-blind RCT assessed outcome in participants continuing topiramate for six additional months open-label, after a six-month treatment period compared to placebo. Placebo-treated subjects showed a higher increase in the number of migraine days and reported lower quality-of-life compared to participants who continued the intake of topiramate (73). Open-label studies have reported sustained benefit after

discontinuation of other oral preventive drugs, onabotulinumtoxinA and CGRP mAbs (74–79). The sustained response is not, however, universal. In some subjects, the therapeutic benefit is short-lasting, and they return to their pre-treatment baseline (80). In these subjects, treatment should be restarted (81). Most international guidelines recommend the use of preventive treatments for six or 12-month periods (Online Supplemental Table 5).

Q6 – What are the success criteria to rate preventive therapy as effective?

Recommendations

Optimal.

The success criteria that determine whether preventive therapy is effective and should be continued according to the recommendations provided in Q5 are any one or more of the following:

- a $\geq 50\%$ decrease in monthly migraine days or moderate-to-severe headache days, optimally based on the use of a headache diary;
- a clinically meaningful subjective improvement as reported by the person with migraine or evaluated by Patient Global Impression scales
- a clinically meaningful improvement in MIDAS or HIT-6 questionnaire scores.

For patients with chronic migraine who have not achieved a $\geq 50\%$ decrease in monthly migraine days or moderate-to-severe headache days with multiple preventive options (including oral drugs, onabotulinumtoxinA and drugs targeting the CGRP pathway), a $\geq 30\%$ decrease in monthly migraine days or moderate-to-severe headache days is acceptable for treatment continuation beyond three months.

Essential.

Given the limited number of options available, it is recommended to continue treatment in all persons with migraine that report a meaningful subjective improvement and who do not have tolerability issues or unwanted side effects.

Background. Expert recommendations suggest that a two- to three-month evaluation period (starting once the maximally tolerated dose has been reached) represents the ideal time interval to evaluate whether a given preventive medication is effective (82). Based on clinical trials and real-world data, most guidelines and recommendations indicate a 50% reduction in the frequency of migraine attacks or monthly migraine days (MMD) or monthly headache days

(MHD) as an acceptable measure of success (Online Supplemental Table 6) (5,7,8,18). A 30% reduction is acceptable for chronic migraine. Clinical trials, however, are designed to evaluate treatment efficacy in ‘controlled’ conditions, and thus the 50% reduction in monthly migraine frequency or MMD may not accurately depict treatment effectiveness in everyday clinical practice. Therefore, in addition to headache frequency and intensity responses, patient-centered outcomes (such as disability, quality of life, medication use for acute migraine attacks, and effect) should be considered (9,14,16).

Evidence. Although used in multiple clinical trials, a 50% response in the reduction of migraine days per month might be too aggressive in clinical practice, and beyond the satisfaction threshold of the person with migraine (14,18). Reductions in headache intensity appear to be as significant for people with migraine as reductions in headache frequency (83,84). Patient-Reported Outcomes (PRO) evaluation tools such as the Migraine-Specific Quality of Life (MSQ) questionnaire and Patient Global Impression of Change (PGIC) can also be considered (85) and have been associated with treatment continuation in a real-world evidence study (86).

The clinically meaningful improvement in MIDAS score is defined by the AHS as i) reduction of ≥ 5 points for baseline score 11–20 or ii) reduction of $\geq 30\%$ for baseline score ≥ 20 . The clinically meaningful improvement in HIT-6 score is a reduction of ≥ 5 points (9).

Q7 – In individuals who have discontinued a migraine preventive after a successful period, what are the criteria for restarting preventive treatment?

Recommendations

Optimal.

In individuals who have discontinued migraine prevention after a successful period of treatment, we suggest waiting at least one month before considering restarting treatment, provided they still satisfy the criteria for prevention (refer to Q1).

Monitoring of headache frequency with a headache diary or a monthly calendar is recommended after stopping a migraine preventive treatment.

Essential.

As described in the optimal recommendations.

Background. Preventive treatment holidays may be recommended in subjects experiencing a meaningful reduction

in migraine days per month who are not severely disabled, in order to determine whether a given preventive is still required and to avoid unnecessary drug exposure (72,82,87). Research suggests that there might be a sustained effect after cessation of certain migraine preventive treatment (73,77,79), however, evidence-based monitoring algorithms for these subjects are lacking.

Evidence. Only one-quarter of persons with migraine adequately responding to prevention with flunarizine or beta-blockers exhibited a sustained response 18 months after terminating treatment. Most (75%) subjects experienced an increase in migraine frequency after a variable period following the discontinuation ranging between one to 28 months (with a mean of 7.2 and 4.4 months in the flunarizine and beta-blockers groups, respectively) (79). Higher attack frequency at baseline, prior history of medication overuse, and poor response to previous preventives were predictors of headache recurrence, decreased effectiveness of subsequent prophylaxis, and lower willingness to receive a new drug (79). A similar six-month study comparing flunarizine with nimodipine reported significant reductions in attack frequency, severity, and duration after discontinuation lasting 8.4 months with the former and 4.9 months with the latter (75). Prevention with topiramate for an additional six-month period after a six-month open label treatment showed sustained improvements with respect to baseline and significantly improved efficacy compared to placebo (73). In contrast, sodium valproate induced sustained relief in only 40% of subjects, although this study included only participants with what is now known as medication overuse headache, and the treatment phase lasted no more than three months (88).

Current data is no better for injectable treatments. One real-life study found that 31% of participants treated with erenumab restarted treatment due to disease rebound to baseline levels at week 4 after treatment completion (87). Furthermore, a pooled analysis of two phase III trials of the anti-CGRP mAb galcanezumab showed that quality of life at the end of a four-month post-treatment period was no different between galcanezumab-treated patients and those who received placebo (89). In a cohort of subjects with migraine treated with erenumab or galcanezumab, $\geq 50\%$ responders-rate dropped from 73.3% to 27.6% in participants with high-frequency episodic migraine, and from 60.6% to 35.5% in participants with chronic migraine at the end of the third month of suspension (90). In another study, almost 90% of participants who had interrupted preventive therapy with CGRP mAbs restarted treatment (91). Additional evidence suggests that, in comparison, migraine worsening might be faster following erenumab discontinuation compared to galcanezumab or fremanezumab suspension (78). This difference is only temporary, however, and all treatment groups return to baseline values in the end (78). Regarding onabotulinumtoxinA, a sustained response at six months has been reported in people with chronic

migraine who attained a reduction in headache days to less than five per month, and of migraine-related disability to mild or less, representing around 40% of the total number of treated subjects (74).

Online Supplemental Table 7 reports the statements regarding monitoring of people with migraine after discontinuation of the preventive treatment in the guidelines reviewed and the guidance documents assessed.

Q8 – Should the choice of migraine preventive drugs be determined by the presence of comorbidities?

Recommendations

Optimal.

The first treatment option should always be a migraine-specific drug.

In individuals with migraine and an ongoing comorbid condition, it is possible to use agents that can provide benefit on both the migraine and the existing comorbidity. This applies specifically to oral preventive treatments (see Table 4).

Essential.

When migraine-specific treatments are not available, the choice of oral preventive treatment should be guided by the presence of comorbidities. We therefore suggest using agents that can provide benefit on both migraine and the existing comorbidity as first line preventive therapy.

Background. Migraine can be associated with several comorbid conditions. Some comorbidities, such as anxiety, depression, acute medication overuse, obesity or insomnia, may also represent a risk factor for the development of chronic migraine (92). Comorbidity is defined as an illness that occurs more frequently in association with a specific disorder than that would be found as a coincidental association in the general population.

Given the numerous drug options available for migraine prevention and the range of existing comorbidities, it can be difficult to predict which drug will a) be safe, b) be tolerable, and c) achieve the highest efficacy. In subjects with comorbidities, oral drugs can offer the opportunity to improve both migraine and the comorbid condition. Examples of this include the use of topiramate for migraine with comorbid obesity or essential tremor, amitriptyline for comorbid insomnia or depression, valproate for bipolar mood disorder or venlafaxine for comorbid depression or generalized anxiety. In certain comorbidities, however, there are drugs that should be avoided, such as valproate in obesity or propranolol in asthma or Raynaud's syndrome. Issues regarding dosing and selection of agents should always be considered. Doses of amitriptyline for depression, for example, are much higher than doses needed for migraine prevention. These higher doses of amitriptyline typically cause more adverse events than lower doses.

The option to treat two conditions with one drug is not typically possible with migraine-specific drugs, although their reduction of migraine symptoms may have an impact on other comorbidities; examples include improving low mood or insomnia when these are caused by migraine pain itself (93). It has also been suggested that the efficacy of anti-CGRP mAbs appears to be independent from comorbidities such as depression.

Table 4. Medications preferred or avoided for preventive treatment of migraine depending on comorbidities.

Class/drug	May be preferred in patient with	Avoid or use with caution in patient with
Tricyclic antidepressants (amitriptyline, nortriptyline)	Insomnia, depression, anxiety, neuropathic pain, comorbid tension-type headache	Heart block, significant cardiovascular disease, urinary retention, uncontrolled glaucoma (especially angle closure type), prostate disease, mania
SNRIs (e.g., venlafaxine)	Depression, anxiety	Hypertension, kidney failure
Valproate	Epilepsy, mania, anxiety, comorbid depression	Liver disease, bleeding disorders, alcoholism, obesity, pregnancy (human teratogen)
Topiramate	Epilepsy, obesity, mania, anxiety, essential tremor, alcohol dependence	Kidney stones, kidney failure, angle closure glaucoma, depression, patients with cognitive concerns, pregnancy
Beta-blockers (propranolol, metoprolol)	Hypertension, angina, comorbid anxiety	Asthma, heart block, congestive heart failure, hypotension, bradycardia, Raynaud's, peripheral vascular disease, insulin-dependent diabetes, sexual dysfunction
Calcium Channel Blockers (flunarizine)	Dizziness, vertigo	Depression, Parkinson's disease
ACEIs/ARBs (candesartan)	Hypertension	Hypotension, pregnancy
OnabotulinumtoxinA	Chronic migraine	Pre-existing dysphagia, breathing difficulties or muscle weakness, myasthenia gravis

ACEIs: angiotensin-converting enzyme (ACE) inhibitors; ARBs: Angiotensin II receptor blockers; SNRIs: Serotonin–norepinephrine reuptake inhibitors.

Evidence. Migraine is associated with both comorbid and concomitant illnesses that influence treatment strategy (92). Various drugs not only have a preventive effect on migraine but also target frequently occurring comorbid conditions (93,94).

A comprehensive list of medications preferred or avoided in the preventive treatment of migraine depending on comorbidities can be found in Table 4.

The approach of using one drug to treat two conditions may, at the same time, also have limitations. One single medication may not treat two different conditions optimally, sometimes two or more medications are required in optimized dosages. Close monitoring after starting one (or multiple) drugs in migraine prevention and comorbidity treatment is usually necessary and referral to an appropriate specialist may be required. Available guidelines on this topic are summarized in Online Supplemental Table 8. It is worth mentioning that some of the guidelines were developed before the advent of migraine-specific treatments.

Q9 – Which preventive medication is suggested for people with chronic migraine?

Recommendations

Optimal.

We suggest atogepant, erenumab, eptinezumab, fremanezumab, galcanezumab, onabotulinumtoxinA and topiramate for people with chronic migraine.

Of note, topiramate should be avoided during pregnancy and in women of childbearing age who are not using highly effective contraception methods.

Essential.

We suggest topiramate, which however must be avoided during pregnancy and in women of childbearing age who are not using highly effective contraception methods. If topiramate is not effective, not tolerated or not indicated, amitriptyline, beta-blockers, valproate can be used.

Combination of two drugs may be necessary, following recommendations provided in Q4.

Background. The current concept of chronic migraine is relatively recent (95). Several drugs approved for preventive migraine treatment were investigated before chronic migraine was officially included in the ICHD and have not been specifically tested in this subgroup of subjects. When compared to episodic migraine, fewer drugs have been formally tested and approved specifically for chronic migraine patients. Nevertheless, most guidelines

consider that preventive drugs with good evidence for the treatment of episodic migraine might also be used for the treatment of chronic migraine, without presenting evidence for the recommendation (Online Supplemental Table 9).

Evidence. Two randomized double-blinded studies support the use of topiramate for the treatment of chronic migraine (36,96). OnabotulinumtoxinA is approved in several countries for the treatment of chronic migraine. The evidence is based primarily on one positive study (PREEMPT 2) and on the pooled analysis of two studies (PREEMPT 1 and PREEMPT 2) (97,98). CGRP mAbs were studied for the treatment of migraine and consistently demonstrated efficacy (49,50,99–102). Among the class of small molecules antagonists of the CGRP receptor, atogepant presented efficacy for the treatment of chronic migraine (103). This trial was recently published and is not yet included in available guidelines. Other drugs with some evidence of efficacy for chronic migraine treatment include valproate and propranolol (104–106). Flunarizine is used in several European countries, with a recommended dose of 5–10 mg, however published trials showing evidence for its efficacy are mostly outdated and of limited quality (107).

Q10 – If a monoclonal antibody targeting the CGRP pathway is not effective, is it beneficial to switch to another anti-CGRP monoclonal antibody?

Recommendations

Optimal.

If a monoclonal antibody targeting the CGRP pathway (anti-CGRP mAb) is ineffective, we suggest switching to another anti-CGRP mAb in individuals who have no other viable therapeutic options among other migraine preventive drug classes due to ineffectiveness, contraindications or tolerability issues.

Essential.

Not applicable.

Background. CGRP-targeted therapies are effective for migraine prevention. The 50% responder rates range from 30% to 60%. Therefore 40–70% of people with migraine do not respond adequately to the CGRP mAbs (108).

Currently, there are up to four CGRP mAbs available in different countries. They have different characteristics in terms of target (CGRP peptide vs. receptor), route of administration (subcutaneous vs. intravenous), flexibility of dose escalation (70 to 140 mg for erenumab and 100 to 300 mg

for eptinezumab) and injection schedule (monthly vs. quarterly for fremanezumab) (108).

Evidence. No controlled head-to-head studies have examined the comparative efficacy of monoclonal antibodies targeting the CGRP pathway. Meta-analyses have shown comparable efficacy, safety and tolerability across the four antibodies (42,66).

Some real-world studies reported the outcome of switching from one to another monoclonal antibody in participants who had insufficient response to the first treatment. One multicenter retrospective study from Germany assessed the $\geq 30\%$ responder rate at month three after switching from erenumab to another antibody (galcanezumab or fremanezumab). The switch from erenumab led to a $\geq 30\%$ response in one-third (32%) of the participants after three months of treatment. A $\geq 50\%$ response was achieved in 12% of the participants (109). Another study from Spain reported a 30% response rate in 50% participants and a 50% response rate in 27% of them when galcanezumab was administered to 15 erenumab non-responders (110).

Despite limited available evidence at this time regarding the efficacy of antibody switching, several guidelines suggest switching as a potential option (Online Supplemental Table 10). The guidelines of the European Headache Federation state that there is insufficient scientific evidence on the potential benefits of antibody switch, but switching may be an option (19). The guidance of the American Headache Society emphasizes that the efficacy and tolerability should be individually evaluated and determined, and that clinical decision making regarding switching to an alternative treatment should be made in a patient-centric fashion (16).

Q11 – What are the possible preventive options for people with migraine who have a positive response to a monoclonal antibody targeting the CGRP pathway, but still have a clinically meaningful residual migraine burden?

Recommendations

Optimal.

In people with migraine who have a positive response to one monoclonal antibody targeting CGRP but still have a clinically meaningful residual migraine burden, we suggest adding a traditional oral preventive drug or, if the person has chronic migraine, onabotulinumtoxinA.

Essential.

Not applicable.

Background. CGRP-targeted therapies induce a 50% reduction of MMDs in a percentage of persons with migraine ranging from 30 to 60% (111). In people with high frequency of chronic migraine, the remaining disease burden may therefore still be high.

Evidence. Preclinical studies suggest that onabotulinumtoxinA and monoclonal antibodies targeting CGRP exert a synergistic effect within the trigeminovascular system, thus favoring this combination (112). RCTs, however, on the efficacy and safety of this dual therapy for migraine prevention are lacking. To date, a limited number of real-world studies have reported that partial responders to onabotulinumtoxinA may benefit from dual therapy with anti CGRP antibodies as an add-on. There is also no evidence that this combination would be harmful. A meta-analysis investigating real-world evidence, showed a reduction of migraine headache days in subjects with migraine who received the combined therapy in comparison to onabotulinumtoxinA alone (113). Those studies suffer from limitations due to the observational nature of the evidence. Additionally, it is unclear if the same benefit could have been obtained with the anti CGRP antibody alone.

Regarding dual therapy with CGRP targeted therapies, the guidelines of the European Headache Federation stated that there is insufficient evidence to make suggestions that the combination of CGRP mAbs with other preventives improves migraine clinical outcomes (19). The guidance document of the American Headache Society suggests adding CGRP mAbs to the existing preventive drugs, without introducing other changes until the effectiveness of the anti-CGRP therapy is observed (16). Considering the favorable tolerability profile of CGRP mAbs and CGRP receptor antagonists, it is possible that their combination may improve the efficacy, without affecting tolerability, but evidence-based data is needed for a clearer view of this option.

The relevant statements of the European Headache Federation and of the American Headache Society are reported in Online Supplemental Table 11.

Q12 – Do greater occipital nerve blocks have a place in migraine prevention?

Recommendations

Optimal.

Greater occipital nerve blocks with local anesthetics, with or without corticosteroids, have limited evidence of efficacy, but may represent an option for migraine prevention. They can also be used in pregnant women.

Essential.

As described in the optimal recommendations.

Comment: Videos on how to perform peripheral nerve anesthetic/steroid blocks are available from the IHS education platform in multiple languages. The links to two videos are provided below:

- Peripheral nerve blocks in headache patients: indications and practical guide; <https://www.youtube.com/watch?v=frlojGkX7C4>
- GON blocks— general aspects and indications; https://www.youtube.com/watch?v=JieNu_YHSTo

Background. Peripheral nerve blocks have emerged over the past decades as a potential treatment option for migraine. The detailed mechanisms of migraine alleviation by peripheral nerve blocks remain uncertain. Modulation of central sensitization is a potential candidate (114). Whether short-acting local anesthetics with/without corticosteroids have a place in migraine prevention is under debate.

Evidence. Several RCTs evaluated the effectiveness of greater occipital nerve blocks (GONB) in migraine prevention. Nine RCTs in particular have assessed GONB outcomes at least four weeks after the first injection.

Six studies (115–120) were conducted in participants with chronic migraine. A meta-analysis (121) included four of them. In the active group, participants received GONB with bupivacaine 0.5% in three studies (pooled $n = 66$) and lidocaine 2% in the remaining one study ($n = 17$). The meta-analysis revealed that headache frequency decreased significantly in the active group receiving during the first (-4.45 days, 95% CI: -6.56 to -2.34 days) and second (-5.49 days, 95% CI: -8.94 to -2.03 days) month as compared to the placebo group. Of note, none of the RCTs reported the preferred primary endpoint suggested by the IHS guidelines for controlled trials of preventive treatment (62,63). Instead, all four studies cross-sectionally compared the pooled headache frequency between active and placebo groups at checkpoints, or longitudinally compared the pooled headache frequency between baseline and treatment phases within each group.

One RCT (116) reported that after receiving three monthly GONB with 2% lidocaine 2 mL for each injection, the reduction in monthly headache days and monthly migraine days from baseline, as well as the 50% responder rate in headache days, were significantly greater in the active group by the end of the blinded phase. The authors ensured blinding by preparing the injection site with lidocaine gel before the actual injection. The same team also conducted an RCT evaluating the combination effect of GONB and topiramate (115). The participants were randomized and allocated to three groups: topiramate monotherapy, topiramate and GONB with lidocaine + methylprednisolone, and topiramate and GONB with lidocaine only. The results showed that as compared with topiramate monotherapy, groups with add-on GONB (with or without methylprednisolone) had greater reductions in monthly migraine days by the end of the study. Groups with add-on GONB (with or without

methylprednisolone) had a higher 50% responder rate in monthly headache days. There were no significant differences between GONB with or without methylprednisolone. To sum up, despite the high heterogeneity between different trials, GONB may be beneficial in the prevention of chronic migraine.

Two placebo-controlled RCTs focused on participants with episodic migraine. In the first (119), weekly injections of GONB plus supraorbital nerve block were administered for three weeks, and reported that the active group had lower headache frequency at the second month. The other study (122) randomly assigned participants into four groups: placebo (saline), lidocaine, triamcinolone, and lidocaine plus triamcinolone. As compared to baseline, the groups receiving GONB with lidocaine and lidocaine plus triamcinolone had lower headache frequency four weeks after a single GONB. However, there were no significant differences between the four groups. Of note, these two studies were also weakened by the abovementioned issue of applying inappropriate primary endpoints.

The remaining two RCTs did not specify whether the participants were diagnosed with episodic or chronic migraine. One study (117) reported negative results with no significant differences in the 50% responder rate between the active group (single GONB with 0.5% bupivacaine + methylprednisolone) and placebo group. Interestingly, to ensure adequate blinding, the authors mimicked the numbness over the injection site by adding 0.25 mL 1% lidocaine into 2.75 mL saline. The possible therapeutic effect of lidocaine, despite its small amount, may have interfered with the results. Another RCT (121) explored triamcinolone in GONB. The participants randomly received a single GONB with 2% lidocaine or 2% lidocaine plus triamcinolone. The preventive effect of lidocaine alone and lidocaine plus triamcinolone was comparable at the 2nd, 6th, and 8th week, as indicated by a similar reduction in headache frequency.

Three RCTs (115,117,122) did not demonstrate the additional benefits of injected corticosteroids. Taking the potential adverse effects of corticosteroid injection (e.g., subcutaneous fat atrophy, hypopigmentation, alopecia) into consideration, use of corticosteroids should be carefully evaluated.

Online Supplemental Table 12 summarizes the statements regarding greater occipital nerve blocks in migraine preventive treatment in the guidelines reviewed and the guidance documents assessed.

Q13 – What are the suggested drugs for migraine prevention in children and adolescents?

Recommendations

Optimal.

In children and adolescents with migraine who need pharmacological migraine prevention, beta-blockers or flunarizine, at doses adapted to body weight, can be used, although evidence of efficacy is very limited.

Essential.

In children and adolescents with migraine who need pharmacologic migraine prevention, beta-blockers, at doses adapted to body weight, can be used, although evidence of efficacy is very limited.

In case of ineffectiveness, low dose topiramate or amitriptyline represent possible alternatives.

Comment: Topiramate should be avoided in female adolescents of childbearing age who are not using highly effective contraception methods.

Background. Migraine is frequently reported among children and adolescents, with an estimated prevalence of ~8%, and its prevalence further increases throughout adolescence (123,124). In school-age children, migraine is associated with more frequent school absenteeism and reduced performance, compared to classmates with no migraine (125). Preventive therapy can be an option when bed rest and acute medication provide insufficient pain relief or when attacks are frequent (71).

Evidence. Evidence is largely lacking for migraine prevention in the pediatric population. The Childhood and Adolescent Migraine Prevention (CHAMP) study, a National Institutes of Health-funded multicenter RCT, is the largest study to evaluate the efficacy of pharmacological therapy for the prevention of migraine in children and adolescents aged 8–17 years (126). This study aimed to compare the preventive effect of topiramate, amitriptyline, and placebo in children with episodic and chronic migraine. The study was stopped early for futility after a planned interim analysis. In all three groups, 50–60% of participants achieved the primary outcomes, defined as $\geq 50\%$ reduction in monthly headache days in the last 28 days of the 24-week treatment compared to baseline. The study also reported more side effects among the topiramate and amitriptyline groups, compared to the placebo group. The authors concluded that the risk:benefit profile of topiramate and amitriptyline is unfavorable. The study, however, showed a placebo response which was higher than in adults.

The effect of flunarizine in children has been documented in one large meta-analysis and seems comparable to that of propranolol (127).

Antiepileptics. Based on data from a pilot study (126), two small RCTs (128,129), and a *post hoc* subgroup analysis (130), topiramate has been suggested to be more effective than placebo at reducing the frequency of monthly headache and migraine days. The Food and Drug Administration (FDA) has also approved topiramate for migraine prevention

in children aged 12 and older. In contrast, the CHAMP study did not support these results (126). Nor did a meta-analysis on the efficacy of topiramate, which found no differences between topiramate and placebo for achieving the $\geq 50\%$ reduction in headache frequency during treatment (131). Thus, the available data is inconclusive regarding whether pediatric subjects with migraine treated with topiramate are more prone than those who receive placebo to experience $\geq 50\%$ reduction in monthly headache or migraine days (10). However, potential side effects following topiramate treatment, such as cognitive disorder, paresthesia and fatigue are well-known (126). Therefore, we recommend that physicians discuss the available evidence and side effects of topiramate in the prevention of pediatric migraine.

Sodium valproate has not been shown to be better than placebo and is associated with adverse events, suggesting it is not an ideal choice in children and adolescents.

Tricyclic antidepressants. One prospective, open-label, single center study demonstrated that amitriptyline can reduce the incidence and intensity of different types of headaches in children (132). Among the different headache disorders included, migraine was the most prevalent diagnosis. The study did not use a $\geq 50\%$ reduction in headache frequency as the primary outcome. We therefore do not believe that there is sufficient data to determine whether pediatric individuals with migraine treated with amitriptyline are more prone than those who receive placebo to experience $\geq 50\%$ reduction in monthly headache or migraine days (132).

Beta-blockers. One network meta-analysis published in 2020 reviewed whether preventive pharmacologic treatments are more effective than placebo in pediatric migraine (133). The authors revealed a significant effect of propranolol 60–120 mg daily compared with placebo. There were no significant differences in adverse events between propranolol and placebo in the short term, while in the long-term analysis, propranolol was not more acceptable than placebo. Therefore, it is possible that pediatric individuals with migraine treated with propranolol are more prone than those who receive placebo to experience $\geq 50\%$ reduction in monthly headache or migraine days (10). However, we recommend weighing the benefits of propranolol against its potential harms.

Online Supplemental Table 13 reports the statements on pharmacological migraine prevention for children and adolescents in the guidelines reviewed and the guidance documents assessed.

Q14 – Which migraine preventive drugs can be used during pregnancy and lactation?

Recommendations

Optimal.

Pregnancy

We suggest non-pharmacologic treatments or peripheral nerve blocks (see Q12) as first line options in pregnant or breastfeeding women. If non-pharmacological treatment is not possible or effective, we suggest propranolol or amitriptyline, after balancing risks and benefits and informing the subject on potential secondary effects and associated risks. Propranolol should be discontinued in the last part of the third trimester to avoid the risk of adverse events to the fetus and neonate.

For persons with chronic migraine, onabotulinumtoxinA may represent an option after balancing risks and benefits given the limited systemic effects.

We strongly recommend avoiding valproate and topiramate during pregnancy due to their teratogenic effects. Similarly, candesartan and lisinopril should be avoided during pregnancy because of the risk of harm and malformation to the fetus.

Breastfeeding

During breastfeeding, non-pharmacologic treatment or peripheral nerve blocks should be considered first line. If non-pharmacologic treatment is not possible or effective, we suggest propranolol or amitriptyline, after informing the subjects of potential secondary effects and associated risks, or onabotulinumtoxinA for persons with chronic migraine. Candesartan can be used with caution. Lisinopril should be avoided.

Monoclonal antibodies targeting CGRP can be used with caution after at least two weeks postpartum.

Essential.

Pregnancy

We suggest non-pharmacologic treatments or peripheral nerve blocks (see Q12) as first line options in pregnant or breastfeeding women. If non-pharmacological treatment is not possible or effective, we suggest propranolol or amitriptyline, after balancing risks and benefits and informing the person with migraine on potential secondary effects and associated risks. Propranolol should be discontinued in the last part of the third trimester to avoid the risk of adverse events to the fetus and neonate.

We strongly recommend avoiding valproate and topiramate during pregnancy due to their teratogenic effects.

Breastfeeding

Non pharmacologic treatment or peripheral nerve blocks should be considered first line. If non-pharmacological treatment is not possible or effective,

we suggest propranolol or amitriptyline, after informing the subjects of the potential secondary effects and associated risks.

Background. Up to 90% of females with migraine experience improvement in migraine during pregnancy, with a significant reduction in the frequency and intensity of their attacks during the second and third trimester of pregnancy (17,134–136). Women who have migraines with aura are at greater risk for having more frequent attacks during pregnancy (137).

Most of the recommended drugs for migraine prevention are FDA pregnancy category C, D or even X as there are no specific clinical trials evaluating drug treatment of migraine during pregnancy and breastfeeding.

Evidence. Based on existing data, although evidence for non-pharmacologic treatment in pregnancy is sparse, this should be the first line considering the potential risk to the fetus of pharmacologic therapy. For this reason, although these recommendations focus specifically on pharmacologic treatment, we have included information on ‘Non-pharmacologic’ therapies below.

Non-pharmacologic therapies. Awareness and avoidance of triggering factors has been considered helpful, even though there is no definitive evidence in migraine treatment (138). Physical fitness has been found to reduce stress and provide a healthy balance between strain and relaxation (139–142).

Behavioral interventions such as relaxation training, thermal biofeedback, electromyographic biofeedback, cognitive behavioral therapy, mindfulness-based therapy and acceptance and commitment therapy may be used alone or in combination with drug therapy to achieve improvement in migraine symptoms (143–147).

Non-invasive neuromodulation including supraorbital electrical nerve stimulation, vagal nerve stimulation and transcranial magnetic stimulation are effective for migraine prevention (148–153). The safety of their use during pregnancy has not yet been established, but animal studies and limited open-label studies have shown no reproducible adverse effects on fetal development (154).

Riboflavin is a vitamin recommended for migraine prevention in persons averse to taking traditional medications (155). Certain vitamins, minerals and herbal preparations have been proposed for preventive therapy in pregnancy and lactation, but they lack the evidence to support their recommendation (145).

Pharmacological therapy. Although beta-blockers have been considered relatively safe in pregnancy, they may be associated with intrauterine growth restriction, hence caution is recommended (156–158). Use of beta-blockers in the third trimester may cause neonatal pharmacologic effects such as bradycardia, hypotension and

hypoglycemia, so the drugs should be tapered or discontinued two to three days before delivery (159,160) to decrease the risk of adverse events to the fetus/neonate and potential reductions in uterine contractions (161). Tricyclic antidepressants are considered the safest second-line option when beta-blockers are contraindicated or ineffective. Amitriptyline is preferred. Some studies suggest a possible teratogenic effect of tricyclic antidepressants (e.g., cardiovascular or limb abnormalities), but a clear causal relationship cannot be proven (135,160,162).

CGRP mAbs are not recommended for use in pregnancy due to lack of studies (19). Other preventive drugs contraindicated include flunarizine, topiramate, sodium valproate and zonisamide (141,160,163,164).

During lactation, valproate and topiramate are classified under Hale Lactation Risk Categories L2 (safer) and L3 (moderately safe), respectively (165,166). According to the Drug and Lactation database (167), propranolol and onabotulinumtoxinA reach low levels in the milk and are considered safe. Amitriptyline may occasionally induce sedation in the infant. Candesartan levels are low in the milk, but caution is advised. No evidence is available on lisinopril, therefore an alternate drug is preferable.

No information is available on the use of CGRP mAbs during breastfeeding. As the four monoclonal antibodies are large protein molecules with a molecular weight of about 143,000 Daltons, the amount in milk is likely to be very low and is probably partially destroyed in the infant's gastrointestinal tract, with low or minimal absorption by the infant. Waiting for at least two weeks postpartum to resume therapy may minimize transfer to the infant. No information is available so far on the clinical use of gepants during breastfeeding.

Peripheral nerve blocks are considered safe in pregnancy and breastfeeding as systemic effects are lower than with use of oral medications. The preferred agent to inject is lidocaine. Bupivacaine or betamethasone may be used as alternatives. Bupivacaine may be associated with fetal cardiotoxicity (168).

Online Supplemental Table 14 reports the statements regarding migraine preventive therapy in pregnancy and lactation in the guidelines reviewed and the guidance documents assessed.

Q15 – Which migraine preventive drugs can be used in people with migraine over 65 years of age?

Recommendations

Optimal.

We suggest selecting the drug for migraine prevention in people with migraine over 65 years after considering

possible comorbidities and the needs of dose adjustments, for all treatments.

We suggest careful clinical monitoring to allow for early detection of adverse effects, as well as the potential need to modify the course of treatment.

Some drugs targeting the CGRP pathway have been tested in populations up to 80 years old without safety issues and can therefore represent an option.

For people with chronic migraine, onabotulinumtoxinA may represent an option given the limited, if any, systemic effect.

Essential.

We suggest selecting the drug for migraine prevention in people with migraine over 65 years after considering possible comorbidities and the needs of dose adjustments, for all treatments.

We suggest careful clinical monitoring to allow for early detection of adverse effects, as well as the potential need to modify the course of treatment.

Background. The rapid growth of the aging population gives rise to the issue of appropriate drug selection for this population. Older adults, aged 65 and older, despite the decreased incidence of headache with age (169), may still require migraine prevention. The selection of an appropriate migraine preventive medication for elderly individuals is complex. These people are more likely to experience other pain syndromes in general, as well as polypharmacy, multiple comorbid medical conditions, and intolerance to pain medication (170,171). Elderly individuals are also typically underrepresented in clinical trials, leading to a significant lack of evidence on drug use (171). These factors account for the complex prescription process for migraine preventive treatment in this population.

Evidence. No guidelines or meta-analyses have been published that offer high-quality data or recommendations regarding migraine prevention in older adults. Only the Danish Guidelines (15) mention 'Elderly patients should only receive half the dose of flunarizine' in passing.

Trials usually exclude individuals older than 65 years old, although recently some trials have started to expand their evaluation to people up to 80 years old. For these reasons, the available information is based on the existing guidelines.

Overall, standard treatment options may be considered for older adults. It is important to use these medications with caution because the elderly have a higher risk of side effects (24,172). When selecting a preventive medication

for migraine, clinicians should take into account any concurrent comorbidity (e.g., cardiovascular disease, asthma, diabetes mellitus) (173). Drugs contraindicated by any comorbid conditions (e.g., β -adrenoceptor antagonists in subjects with asthma) and drugs that could worsen migraine (e.g., nifedipine in individuals with hypertension) should be avoided whenever possible. Particular attention should be also given to drug-drug or drug-food interactions (174).

The use of tricyclic antidepressants in older individuals may be associated with higher plasma concentrations and metabolites compared to younger people, leading to an increased incidence of adverse events (175). Amitriptyline can cause cardiac conduction abnormalities, orthostatic hypotension, seizures, cognitive impairment and confusion, thus strongly limiting its indication in older adults (176). Further, tricyclic antidepressants are effective, especially in individuals with comorbid insomnia, mood and anxiety disorders but contraindicated in people with glaucoma or prostatic hypertrophy. Additionally, tricyclic antidepressants should be avoided in people with recent myocardial infarction or with prolonged QTc intervals, since a mean prolongation of 10–20 msec has been reported in treated elderly individuals (171). Finally, they are contraindicated in subjects with heart failure or co-administration with monoamine oxidase inhibitors. We suggest the administration of small doses between 10 and 30 mg with slow titration (177).

Among the antidepressants, excluding venlafaxine, the use of selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs) for the preventive treatment of migraine is not supported by evidence (178). In older individuals, studies have shown that there is a strong association between developing hyponatremia after treatment with SSRIs and venlafaxine. Therefore, monitoring of sodium levels is recommended (179). Overall, venlafaxine has moderate evidence for migraine prevention with fewer side effects than amitriptyline, which makes it a favorable option to consider in older adults (180), with a recommended dose of 75–150 mg/daily (181).

The use of beta-blockers, a first-line drug for migraine prevention, needs to be restricted in the elderly population since these drugs may worsen congestive heart failure, promote conduction disorders or exacerbate asthma, diabetes, glaucoma or depressive symptoms (177). Beta-blockers might be a drug of choice for migraine prevention in elderly adults if they have concomitant hypertension or coronary artery disease (174,181). Lisinopril and candesartan are drugs with low levels of recommendation for preventing migraines but have not been shown to increase side effects in subjects over 65 (182).

The unfavorable adverse effects profile usually limits the use of antiepileptics in the elderly (171). Among antiepileptic drugs, topiramate has strong evidence for migraine prevention and can be used in the elderly. It is, however, contraindicated in individual suffering from nephrolithiasis and glaucoma (174,181). Topiramate use

is also linked with paresthesia, taste disturbances, reduction of cognitive performance – particularly presenting word-finding difficulty – and weight loss (183). Valproate is contraindicated in persons with liver disease and thrombocytopenia. Moreover, its use in older adults should be cautious because this drug can cause liver dysfunction, hyperammonemia, decreased bone marrow density, delirium, tremor and ataxia (177,184).

The use of calcium channel blockers in the elderly should only be considered after a careful evaluation of the associated risks (174). Flunarizine should be avoided in individuals with hypotension, heart failure, atrioventricular block, Parkinson's disease, familial risk of Parkinson's disease or depression (185). For these reasons, the Danish guidelines suggest that older adults should only receive half the dose of flunarizine (15).

OnabotulinumtoxinA is a relatively safe and useful option in people with drug-resistant chronic migraine as it has few side effects and has already been largely used in other neurological conditions such as spasticity in older adults (177,186,187).

CGRP-targeting agents can be administered in older adults, but their use is not yet recommended by guidelines (170,172). Although most of the data from clinical trials involving CGRP mAbs are derived from individuals with migraine younger than 65 years, emerging data support the possibility of safely using them in the elderly. The latest data from clinical trials now available include adults as old as 70/75 years of age, suggesting an acceptable safety profile. This is the case of fremanezumab (188) that was assessed in individuals up to 70 years old and eptinezumab that was assessed in individuals up to age 75 (33,189). The age of a person does not affect the efficacy of galcanezumab in preventing migraine attacks, and there is no clinically meaningful influence of age on its pharmacokinetics (190). Galcanezumab was tested up to age 75 and pooled data from available trials suggest that there is no need to adjust the dose for older people (191). Erenumab has not been tested in persons with migraine older than 65 years, but it has a similar safety profile to placebo across younger age groups in individuals with episodic or chronic migraine and it was well tolerated in older participants with multiple comorbidities, polypharmacy, and age-related physiological changes (192). While these studies provide preliminary evidence that using CGRP mAbs is safe in individuals beyond 65 years, more research is needed in larger populations of older people.

Emerging data support the possibility to use gepants as well in older adults, but most clinical trials included few participants older than 65 years (193), although recent trials on atogepant included participants up to 80 years of age (103,194,195). Rimegepant appeared effective in trials also involving elderly participants (196,197) and it

was reported as safe and well tolerated in adults older than 65 years old, following a single oral 75 mg dose (198). Overall, despite lacking specific trials addressing the elderly population, gepants are likely to be well tolerated by the older population, although their hepatic metabolism warrants a careful evaluation during polypharmacy (170).

A group of experts has recently proposed the use of candesartan or beta-blockers without partial agonist activity (e.g., bisoprolol, propranolol, metoprolol, nadolol, or atenolol) as first-line treatments for migraine prevention, while antidepressants (e.g., amitriptyline and venlafaxine) and anticonvulsants (e.g., sodium valproate and topiramate) are suggested as second-line preventive medications, requiring particular caution in older adults (199). The third line is represented by onabotulinumtoxinA, the CGRP mAbs and CGRP receptor antagonists.

Q16 – What is the recommended approach to people with migraine and medication overuse?

Recommendations

Optimal.

In people with migraine and medication overuse the following approaches are recommended:

- reduced intake of overused drug(s) simultaneous with the initiation of preventive treatment;
- reduced intake of overused drug(s) followed by initiation of preventive treatment;
- interruption of overused drug(s) followed by initiation of preventive treatment.

The selection of the preventive treatment must be based on evidence of therapeutic efficacy, personal history and comorbidities.

Monoclonal antibodies targeting the CGRP pathway, topiramate and onabotulinumtoxinA have proven effective regardless of the presence of medication overuse, therefore the immediate withdrawal or reduction of the overused drug might not be necessary in subjects who are initiating such a treatment.

Individuals overusing opioids or barbiturate containing drugs may require hospitalization to manage drug discontinuation safely and successfully.

Essential.

In people with migraine and medication overuse the following approaches are recommended:

- reduced intake of overused drug(s) simultaneous with the initiation of preventive treatment;
- reduced intake of overused drug(s) followed by initiation of preventive treatment;
- abrupt interruption of overused drug(s) followed by initiation of preventive treatment.

The selection of the preventive treatment must be based on evidence of therapeutic efficacy, personal history and comorbidities.

Topiramate has proven effective regardless of the presence of medication overuse, therefore the immediate withdrawal or reduction of the overused drug might not be necessary in subjects who are initiating such a treatment.

Individuals overusing opioids or barbiturate containing drugs may require careful monitoring to manage drug discontinuation safely and successfully.

Background. Medication overuse headache (MOH) is defined as headache occurring on 15 or more days/month in an individual with a pre-existing primary headache disorder, which develops due to regular overuse of acute or symptomatic headache medication. Medication overuse is defined as regular intake for more than three months of: > 15 days/month of paracetamol or NSAIDs; > 10 days/month of triptans, ergotamine, opioids or combination-analgesics (200).

MOH represents a significant issue within headache management, as it is associated with substantial disability and reductions in quality of life, and very often goes underrecognized in clinical practice. It presents in more than half the people who have headache on >15 days/month, and is estimated to affect around 59 million people worldwide (201,202).

Evidence. MOH is most commonly seen in people with a pre-existing diagnosis of either migraine or tension-type headache (203) and results from an interaction between frequently used acute headache medication and individual susceptibility. Certain risk factors are associated with developing MOH, such as female gender, low socioeconomic status, presence of a concomitant painful condition and psychiatric comorbidities (204).

For the management of MOH, a patient-centered approach and education on the condition are crucial (205). Evidence from RCTs has in fact shown that advice alone can determine similar treatment outcomes to pharmacological interventions in individuals with uncomplicated MOH (206).

In general, the majority of people with MOH improve on withdrawal of the overused medication, and conversely MOH is less likely to resolve unless the overused medication is stopped (207). Withdrawal itself has shown to be more effective when the drug is eliminated completely rather than restricted (208), particularly when associated with early start

of preventive medication (209). For prevention, specific drugs that have shown efficacy in MOH include topiramate (37), valproic acid (210) and onabotulinumtoxinA (211). As regards this latter, one study showed that the improvement is related to the withdrawal from overused drugs rather than to the administration of the drug (212).

Although drug withdrawal can certainly be effective, the timing and even absolute necessity of it is still debated. One study used a 'pragmatic approach' to MOH and showed that, as long as appropriate preventive medication was started, switching or limiting symptomatic medication was just as effective as not switching at all (213). Recent subgroup analyses of studies investigating CGRP mAbs have shown promising results in MOH even without strict discontinuation (214–216), indicating that novel treatments might change the approach to the condition in the future. These studies did not, however, include individuals with opioid overuse. Overall, the data suggests that even the use of acute analgesics two to three days a week can potentially have an impact on efficacy of concomitant preventive treatment (217).

Online Supplemental Table 15 reports the statements on the approach to medication overuse in the guidelines reviewed and the guidance documents assessed.

Declaration of conflicting interests

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article:

Francesca Puledda declares speaker and consultancy fees from Abbvie and Teva. Simona Sacco declares grants/contracts, consulting fees or honoraria from Novartis, Uriach, Allergan-Abbvie, Teva, Lilly, Lundbeck, Pfizer, NovoNordisk, Abbott, AstraZeneca, Pfizer. Hans-Christoph Diener received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from: AbbVie, Lilly, Lundbeck, Novartis, Pfizer, Teva and WebMD. The German Research Council (DFG) supports headache research by HCD. HCD serves on the editorial boards of *Cephalalgia*, *Lancet Neurology* and *Drugs*. Messoud Ashina is a consultant, speaker, or scientific advisor for AbbVie, Amgen, Astra Zeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Novartis, Pfizer, and Teva; a primary investigator for ongoing AbbVie and Pfizer trials; and is the past president of the International Headache Society. MA is supported through the Lundbeck Foundation Professor Grant (R310-2018-3711) and received institutional research grant from Lundbeck and Novartis. MA serves as associate editor of *Journal of Headache Pain*, and associate editor of *Brain*. Sait Ashina has received honoraria for consulting from Allergan/Abbvie, Eli Lilly, Impel NeuroPharma, Linpharma, Lundbeck, Pfizer, Satsuma, Teva, Theranica. SA is an associate editor for *Neurology Reviews*, *BMC Neurology*, and *Frontiers in Neurology*, and serves on the editorial board for *Journal of Headache Pain*. SA serves as a Trustee on the Board of the International Headache Society and is a member of the Education Committee of the International Headache Society. Eric Liebler declares consulting fees from ElecCore, Inc. Andrea Cipriani is supported by the National Institute for Health

Research (NIHR) Oxford Cognitive Health Clinical Research Facility, by an NIHR Research Professorship (grant RP-2017-08-ST2-006), by the NIHR Oxford and Thames Valley Applied Research Collaboration and by the NIHR Oxford Health Biomedical Research Centre (grant NIHR203316). The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the UK Department of Health. Min Kyung Chu was a site investigator for a multicenter trial sponsored by Biohaven Pharmaceuticals, Allergan Korea, and Ildong Pharmaceutical Company. He received lecture honoraria from Eli Lilly and Company, Handok-Teva, and Ildong Pharmaceutical Company over the past 24 months. He received grants from Yonsei University College of Medicine (6-2021-0229), the Korea Health Industry Development Institute (KHIDI) (Grant No.: HV22C0106), and a National Research Foundation of Korea (NRF) grant. Alexandra Cocores declares grants/contracts from AbbVie, Eli Lilly, Rehaler. Esme Ekizoğlu declares honoraria from Allergan-Abbvie. David Garcia-Azorin declares grants/contracts from Carlos III Research and Castilla and Leon Regional Health, consulting fees from Eli-Lilly, WHO, Lundbeck or honoraria from AbbVie, Teva, Novartis, Pfizer. Carl Göbel declares honoraria from Fielmann AG and German Society for the Study of Pain. Maria Teresa Goicochea, personal fees as speaker or advisory board and/or non-financial support from Pfizer, AbbVie and Teva. Amr Hassan declares consulting fees or honoraria from Novartis, Sanofi Genzyme, Biologix, Merck, Hikma Pharma, Janssen, Inspire Pharma, Future Pharma, Elixir pharma, Allergan, Merck, Biologix, Roche, Bayer, Chemipharma, Al Andalus, and Clavita Pharm. Koichi Hirata declares consulting fees from Otsuka Pharma, and honoraria from Amgen Astellas BioPharma KK, Daiichi Sankyo, Eisai, Eli Lilly Japan KK, MSD, Otsuka Pharma, Pfizer Japan, and Sawai Pharma. Jan Hoffmann declares grants/contracts from Bristol Myers Squibb, International Headache Society (IHS), National Institute for Health and Care Research (NIHR), Medical Research Council (MRC) and Migraine Trust, consulting fees or honoraria from AbbVie, Cannovex, Eli Lilly, Novartis, Teva, Allergan, Chordate Medical AB, Lundbeck, Sanofi, MD Horizonte, Pfizer, Sage, NEJM Journal Watch Neurology, Oxford University Press, Quintessence Publishing, Springer Healthcare. He holds stock options from Chordate Medical AB. Bronwyn Jenkins declares honoraria from Allergan/Abbvie, Eli-Lilly, Novartis, Pfizer, Teva, Viatrix. Katharina Kamm declares grants/contracts from the German Headache and Migraine Society, Novartis, consulting fees from Hormosan, and honoraria from Lundbeck, TEVA, derCampus, Novartis. Mi Ji Lee declares consulting fees or honoraria from Eli-Lilly, Lundbeck, Pfizer, NuEyne Co, Teva AbbVie, SK Chemical, CKD Pharma, and YuYu. Marco Lisicki declares honoraria from Teva, AbbVie, Novartis, Pfizer and Allergan. Daniele Martinelli declares honoraria from AbbVie and Lundbeck. Teshamae S. Monteith has the following disclosures over the past three years: clinical trial site principal investigator for studies sponsored by Abbvie, Eli Lilly, Ipsen and Rehaler, participation in advisory board/consultancy for AbbVie, Teva, Linpharma, e-Neura, Novartis, Merz, and Pfizer, Educational grant from Amgen and AbbVie, personal fees from Medscape, Massachusetts Medical Society, American Headache Society, American Academy of Neurology, Neurodiem,

Academic CME, AbbVie, Novartis, unpaid co-author for research funded by AbbVie, Pfizer/Biohaven, and Theranica. She is an associate editor for *Cephalalgia* and *Continuum Audio*, and is on the editorial board for *Neurology*, *American Migraine Foundation*, and *Brain and Life Magazine*. Dr Monteith has provided unpaid service on the board of directors for the International Headache Society (2021-2023) and currently on the executive board for the Florida Society of Neurology. Raffaele Ornello declares grants/contracts from Novartis, consulting fees/honoraria from Eli Lilly, AbbVie, Pfizer, and Teva. Aynur Özge declares consulting fees or honoraria from AbbVie Lilly, Teva, Abdi Ibrahim, İlko and Drogosan. Mario Peres accepted honoraria for lectures, presentations, speakers' bureaus, manuscript writing and educational events from Pfizer, Teva, AbbVie-Allergan, Lundbeck. Accepted travel support from Teva. Participated in advisory boards, AbbVie-Allergan, Eli Lilly, Pfizer, Kenvue, Eurofarma, Sanofi-Aventis. MP is president of ABRACES. Patricia Pozo-Rosich declares grants/contracts from ERANet Neuron, Instituto Salud Carlos III, Novartis, Teva and AbbVie and consulting fees or honoraria from AbbVie, Almirall, Eli Lilly, Lundbeck Medscape, Novartis, Pfizer, Teva. Todd J. Schwedt declares grants/contracts with American Heart Association, Amgen, Henry Jackson Foundation, National Headache Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute, Pfizer, Spark Neuro, United States Department of Defense, American Migraine Foundation and Mayo Clinic. Consulting fees from AbbVie, Allergan, Amgen, Axsome, Biodelivery Science, Biohaven, Click Therapeutics, Collegium, Eli Lilly, Equinox, Ipsen, Unpharma, Lundbeck, Novartis, Satsuma, Scilex, Theranica, and Tonix. He declares royalties from UpToDate and stock options from Aural. Marcio Nattan P. Souza declares consulting fees or honoraria from Teva, Libbs, Pfizer, Sandoz, Lundbeck, Allergan/AbbVie, Lilly. Tsubasa Takizawa declares grants/research funds from Eli Lilly, Pfizer and Tsumura and advisory/consulting fees and/or honoraria from Eli Lilly, Daiichi Sankyo, Otsuka, Amgen, Teijin, Pfizer, Kyowa Kirin, Eisai, Kowa, UCB Japan, Takeda, and Santen Pharma. Gisela M. Terwindt declares grants/contracts from European Community, Dutch Heart Foundation, IRRF, Dioraphte and Dutch Brain Council with consulting fees or honoraria from Novartis, Lilly, Teva, AbbVie/Allergan, Lundbeck, Pfizer, Spring Media, Ashfield MedComms, Remedica Cygnea. Nicolas Vandenbussche declares consulting fees or honoraria from Pfizer, AbbVie, Novartis, Teva, Babinski VZW, ACREHAB UGent. Shuu-Jiun Wang declares honoraria from AbbVie, Pfizer and Biogen. Cristina Tassorelli declares grants/contracts from AbbVie with consulting fees or honoraria from AbbVie, Eli Lilly, Dompé, Ipsen, Lundbeck, Pfizer, Medscape, Teva. All remaining authors report no disclosures or conflicts of interest.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Francesca Puledda  <https://orcid.org/0000-0002-1933-4049>
Hans-Christoph Diener  <https://orcid.org/0000-0002-6556-8612>

Haidar M Al-Khazali  <https://orcid.org/0000-0001-7015-3369>
Sait Ashina  <https://orcid.org/0000-0003-3973-6640>
Rami Burstein  <https://orcid.org/0000-0003-3763-8916>
Min Kyung Chu  <https://orcid.org/0000-0001-6221-1346>
David Garcia-Azorin  <https://orcid.org/0000-0002-3132-1064>
Jan Hoffmann  <https://orcid.org/0000-0002-2103-9081>
Katharina Kamm  <https://orcid.org/0000-0002-1891-1799>
Mi Ji Lee  <https://orcid.org/0000-0003-1364-1969>
Yu-Hsiang Ling  <https://orcid.org/0000-0003-2360-0693>
Marco Lisicki  <https://orcid.org/0000-0001-9765-6759>
Daniele Martinelli  <https://orcid.org/0000-0001-6355-7947>
Teshamae S Monteith  <https://orcid.org/0000-0001-8912-252X>
Raffaele Ornello  <https://orcid.org/0000-0001-9501-4031>
Mario Fernando Prieto Peres  <https://orcid.org/0000-0002-0068-1905>
Patricia Pozo-Rosich  <https://orcid.org/0000-0003-0796-4702>
Todd J Schwedt  <https://orcid.org/0000-0002-7780-7086>
Marcio Nattan P Souza  <https://orcid.org/0000-0003-4841-4491>
Janu Thuraiaiyah  <https://orcid.org/0000-0002-7166-0976>
Mansoureh Togha  <https://orcid.org/0000-0002-9368-6835>
Shuu-Jiun Wang  <https://orcid.org/0000-0001-5179-5358>
Shenguan Yu  <https://orcid.org/0000-0001-8933-088X>
Cristina Tassorelli  <https://orcid.org/0000-0003-1513-2113>

Supplemental Material

Supplemental material for this article is available online.

References

1. World Health Organization. World Health Organization Model List of Essential Medicines 2023. <https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02> (accessed 1st October 2023).
2. Puledda F, Sacco S, Diener H-C, et al. Global practice recommendations of the international headache society for the acute pharmacological treatment of migraine. *Cephalalgia* 2024 Aug; 44: 3331024241252666.
3. Smith KA, Blease C, Faurholt-Jepsen M, et al. Digital mental health: challenges and next steps. *BMJ Mental Health* 2023; 26: e300670.
4. Snow V, Weiss K, Wall EM, et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. *Ann Intern Med* 2002; 137: 840-849.
5. Evers S, Afra J, Frese J, et al. EFNS Guideline on the drug treatment of migraine—revised report of an EFNS task force. *Eur J Neurol* 2009; 16: 968-981.
6. Canadian Headache society guideline for migraine prophylaxis: supplement 2. *Can J Neurol Sci* 2012; 39: i-63.
7. Toward Optimized Practice (TOP) Headache Working Group. *Primary Care Management of Headache in Adults: Clinical Practice Guideline: 2nd Edition*. 2016. <http://www.topalbertadoctors.org/cpgs/10065> (accessed 21 August 2024).
8. SIGN 155. Pharmacological Management of Migraine. A National Clinical Guideline. <https://www.sign.ac.uk/media/2077/sign-155-migraine-2023-update-v3.pdf> (2023, accessed 12 May 2023).
9. American Headache Society. The American headache society position statement on integrating new migraine treatments into clinical practice. *Headache* 2019; 59: 1-18.

10. Oskoui M, Pringsheim T, Billingshurst L, et al. Practice guideline update summary: pharmacologic treatment for pediatric migraine prevention: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology* 2019; 93: 500–509.
11. British Association for the Study of Headache. Headache Management System for Adults 2019. <https://headache.org.uk/wp-content/uploads/2023/02/bash-guideline-2019.pdf> (2019, accessed 12 May 2023).
12. Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition) : on behalf of the European headache federation and lifting the burden: the global campaign against headache. *J Headache Pain* 2019; 20: 57.
13. Santos Lasaosa S and Pozo-Rosich P. Manual de Práctica Clínica en Cefaleas. Recomendaciones Diagnóstico-Terapéuticas de la Sociedad Española de Neurología 2020. <https://www.sen.es/pdf/2020/ManualCefaleas2020.pdf> (accessed 21 August 2024).
14. National Institute for Health and Care Excellence (NICE). Headaches in over 12s: Diagnosis and management. (NICE Guideline, No. 150.) 2021. Dec 17. <https://www.ncbi.nlm.nih.gov/books/NBK553317/> (accessed 12 May 2023).
15. Schytz HW, Amin FM, Jensen RH, et al. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd ed., 2020. *J Headache Pain* 2021; 22: 22.
16. Ailani J, Burch RC and Robbins MS. The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. *Headache* 2021; 61: 1021–1039.
17. Ducros A, de Gaalon S, Roos C, et al. Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: pharmacological treatment. *Rev Neurol (Paris)* 2021; 177: 734–752.
18. Diener HC, Förderreuther S and Kropp P. Treatment of migraine attacks and preventive treatment of migraine (English): Deutsche Gesellschaft für Neurologie (Hrsg.); 2022. https://ihs-headache.org/wp-content/uploads/2023/06/DMKG_Treatment-of-migraine-attacks-and-preventive-treatment-of-migraine-2022.pdf (accessed 7 February 2023).
19. Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. *J Headache Pain* 2022; 23: 67.
20. Lau CI and Wang YF. 2022 Taiwan guidelines for acute treatment of migraine. *Acta Neurol Taiwan* 2022; 31: 89–113.
21. Korean Headache Society. Korean Headache Society Guidelines 2023. https://www.headache.or.kr/bbs/board.php?bo_table=3_5_1_1&wr_id=4 (accessed 27 March 2023).
22. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of disease study 2016. *Lancet Neurol* 2018; 17: 954–976.
23. GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the global burden of disease study 2021. *Lancet Neurol* 2024; 23: 344–381.
24. Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. *Lancet* 2021; 397: 1505–1518.
25. Tassorelli C, Tedeschi G, Sarchielli P, et al. Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. *Expert Rev Neurother* 2018; 18: 167–176.
26. Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. *J Headache Pain* 2018; 19: 91.
27. Schwedt T, Reuter U, Tepper S, et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. *J Headache Pain* 2018; 19: 1–8.
28. Dodick DW, Silberstein SD, Lipton RB, et al. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: analysis of PREEMPT data. *Cephalalgia* 2019; 39: 945–956.
29. Goadsby PJ, Dodick DW, Martinez JM, et al. Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. *J Neurology* 2019; 90: 939–944.
30. Winner PK, Spierings EL, Yeung PP, et al. Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. *Headache* 2019; 59: 1743–1752.
31. Schwedt TJ, Kuruppu DK, Dong Y, et al. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. *J Headache Pain* 2021; 22: 1–9.
32. Ailani J, McAllister P, Winner PK, et al. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial. *BMC Neurology* 2022; 22: 205.
33. Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. *Lancet Neurol* 2022; 21: 597–607.
34. Schwedt TJ, Lipton RB, Ailani J, et al. Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. *Cephalalgia* 2022; 42: 3–11.
35. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. *Lancet* 2021; 397: 51–60.
36. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. *Headache* 2007; 47: 170–180.
37. Diener H, Bussone G, Oene JV, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. *Cephalalgia* 2007; 27: 814–823.
38. Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients

- receiving topiramate for migraine prevention in controlled trials. *Pain Med* 2008; 9: 175–185.
39. Evans RW, Bigal ME, Grosberg B, et al. Target doses and titration schedules for migraine preventive medications. *Headache* 2006; 46: 160–164.
 40. Ehrlich M, Hentschke C, Sieder C, et al. Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study. *J Headache Pain* 2022; 23: 1–8.
 41. García-Azorín D, Martínez B, Gutiérrez M, et al. Real-World evaluation of the tolerability to onabotulinum toxin A: the RETO study. *Toxins* 2022; 14: 850.
 42. Messina R, Huessler EM, Puledra F, et al. Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and meta-analysis. *Cephalalgia* 2023; 43: 3331024231152169.
 43. Vecsei L, Majlath Z, Szok D, et al. Drug safety and tolerability in prophylactic migraine treatment. *Exp Opin Drug Safety* 2015; 14: 667–681.
 44. Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. *J Headache Pain* 2017; 18: 101.
 45. de Vries Lentsch S, Verhagen IE, van den Hoek TC, et al. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: a real-life study. *Eur J Neurol* 2021; 28: 4194–4203.
 46. Guerzoni S, Pellesi L, Baraldi C, et al. Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. *J Headache Pain* 2016; 17: 1–8.
 47. Hepp Z, Bloudek LM and Varon SF. Systematic review of migraine prophylaxis adherence and persistence. *J Manag Care Pharm* 2014; 20: 22–33.
 48. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. *Lancet* 2018; 392: 2280–2287.
 49. Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. *Lancet* 2019; 394: 1030–1040.
 50. Mulleners WM, Kim B-K, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. *Lancet Neurol* 2020; 19: 814–825.
 51. Blumenfeld AM, Stark RJ, Freeman MC, et al. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. *J Headache Pain* 2018; 19: 13.
 52. Ahmed F, Gaul C, García-Moncó JC, et al. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. *J Headache Pain* 2019; 20: 26.
 53. Rothrock JF, Adams AM, Lipton RB, et al. FORWARD Study: evaluating the comparative effectiveness of OnabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. *Headache* 2019; 59: 1700–1713.
 54. Shamlilyan TA, Kane RL and Taylor FR. *Migraine in adults: preventive pharmacologic treatments*. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ), 2013. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/migraine-prevention_research-2013.pdf.
 55. Silberstein SD, Dodick DW, Lindblad AS, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. *Neurology* 2012; 78: 976–984.
 56. Domingues RB, Silva AL, Domingues SA, et al. A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine. *Arg Neuropsiquiatr* 2009; 67: 973–977.
 57. Ailani J and Blumenfeld AM. Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine. *Headache* 2022; 62: 106–108.
 58. Cohen F, Armand C, Lipton RB, et al. Efficacy and tolerability of calcitonin gene-related peptide-targeted monoclonal antibody medications as add-on therapy to OnabotulinumtoxinA in patients with chronic migraine. *Pain Med* 2021; 22: 1857–1863.
 59. Argyriou AA, Dermizakis EV, Xiromerisiou G, et al. OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine. *Toxins (Basel)* 2022; 14: 847.
 60. Pascual J, Leira R and Láinez JM. Combined therapy for migraine prevention? Clinical experience with a beta-blocker plus sodium valproate in 52 resistant migraine patients. *Cephalalgia* 2003; 23: 961–962.
 61. Krymchantowski AV, da Cunha Jevoux C and Bigal ME. Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders. *J Headache Pain* 2012; 13: 53–59.
 62. Diener H-C, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. *Cephalalgia* 2020; 40: 1026–1044.
 63. Tassorelli C, Diener H-C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. *Cephalalgia* 2018; 38: 815–832.
 64. Haghdoust F, Puledra F, Garcia-Azorin D, et al. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials. *Cephalalgia* 2023; 43: 3331024231159366.
 65. Jackson JL, Cogbill E, Santana-Davila R, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. *PloS One* 2015; 10: e0130733.
 66. Lanteri-Minet M, Ducros A, Francois C, et al. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: a meta-analysis on 10 years of real-world data. *Cephalalgia* 2022; 42: 1543–1564.
 67. Rapoport A, Mauskop A, Diener HC, et al. Long-term migraine prevention with topiramate: open-label extension of pivotal trials. *Headache* 2006; 46: 1151–1160.

68. Ashina M, Goadsby PJ, Reuter U, et al. Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. *Euro J Neurol* 2021; 28: 1716–1725.
69. Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. *Neurology* 2020; 95: e2487–e2499.
70. Pozo-Rosich P, Detke HC, Wang S, et al. Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. *Curr Med Res Op* 2022; 38: 731–742.
71. Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. *Nat Rev Neurol* 2021; 17: 501–514.
72. Al-Hassany L, Lyons HS, Boucherie DM, et al. The sense of stopping migraine prophylaxis. *J Headache Pain* 2023; 24: 9–9.
73. Diener H-C, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2007; 6: 1054–1062.
74. Ching J, Tinsley A and Rothrock J. Prognosis following discontinuation of OnabotulinumA therapy in “super-responding” chronic migraine patients. *Headache* 2019; 59: 1279–1285.
75. Martínez-Lage JM. Flunarizine (sibelium) in the prophylaxis of migraine. An open, long-term, multicenter trial. *Cephalalgia* 1988; 8: 15–20.
76. Nsaka M, Scheffler A, Wurthmann S, et al. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies. *Brain Behavior* 2022; 12: e2662.
77. Nuti A, Lucetti C, Pavese N, et al. Long-term follow-up after flunarizine or nimodipine discontinuation in migraine patients. *Cephalalgia* 1996; 16: 337–340.
78. Raffaelli B, Terhart M, Overeem LH, et al. Migraine evolution after the cessation of CGRP (-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. *Cephalalgia* 2022; 42: 326–334.
79. Wöber C, Wöber-Bingöl C, Koch G, et al. Long-term results of migraine prophylaxis with flunarizine and beta-blockers. *Cephalalgia* 1991; 11: 251–256.
80. Bhoi SK, Kalita J and Misra UK. Is 6 months of migraine prophylaxis adequate? *Neurological Res* 2013; 35: 1009–1014.
81. Raffaelli B, Terhart M, Mecklenburg J, et al. Resumption of migraine preventive treatment with CGRP (-receptor) antibodies after a 3-month drug holiday: a real-world experience. *J Headache Pain* 2022; 23: 1–8.
82. Mathew NT and Tfelt-Hansen P. General and pharmacologic approach to migraine management. In: Olesen J, Goadsby PJ, Ramadan NM, et al. (eds.), *The Headaches*. 3rd ed. Philadelphia, USA: Lippincott & Williams, 2005, 433–440.
83. Becker WJ. Acute migraine treatment in adults. *Headache* 2015; 55: 778–793.
84. Torres-Ferrus M, Gallardo VJ, Alpuente A, et al. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA. *J Headache Pain* 2020; 21: 88.
85. Diener HC, Ashina M, Durand-Zaleski I, et al. Health technology assessment for the acute and preventive treatment of migraine: a position statement of the International Headache Society. *Cephalalgia* 2021; 41: 279–293.
86. Alpuente A, Gallardo VJ, Caronna E, et al. In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. *J Headache Pain* 2021; 22: 151.
87. De Matteis E, Affaitati G, Frattale I, et al. Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. *Neurological Sciences* 2021; 42: 3297–3303.
88. Rothrock JF and Mendizabal JE. An analysis of the “carry-over effect” following successful short-term treatment of transformed migraine with divalproex sodium. *Headache* 2000; 40: 17–19.
89. Stauffer VL, Wang S, Voulgaropoulos M, et al. Effect of galcanezumab following treatment cessation in patients with migraine: results from 2 randomized phase 3 trials. *Headache* 2019; 59: 834–847.
90. Vernieri F, Brunelli N, Messina R, et al. Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. *J Headache Pain* 2021; 22: 1–10.
91. Gantenbein AR, Agosti R, Gobbi C, et al. Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment – a real-life cohort study. *Cephalalgia* 2021; 41: 1181–1186.
92. Xu J, Kong F and Buse DC. Predictors of episodic migraine transformation to chronic migraine: a systematic review and meta-analysis of observational cohort studies. *Cephalalgia* 2020; 40: 503–516.
93. de Vries Lentsch S, van der Arend BWH, de Boer I, et al. Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine. *Eur J Neurol* 2024; 31: e16106.
94. Silberstein SD, Dodick D, Freitag F, et al. Pharmacological approaches to managing migraine and associated comorbidities—clinical considerations for monotherapy versus polytherapy. *Headache* 2007; 47: 585–599.
95. Medrea I and Christl S. Chronic migraine – evolution of the concept and clinical implications. *Headache* 2018; 58: 1495–1500.
96. Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. *JAMA* 2004; 291: 965–973.
97. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. *Cephalalgia* 2010; 30: 793–803.
98. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia* 2010; 30: 804–814.
99. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a

- randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Neurol* 2017; 16: 425–434.
100. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. *New Eng J Med* 2017; 377: 2113–2122.
 101. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. *Neurology* 2018; 91: E2211–E2221.
 102. Dodick DW, Lipton RB, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. *Cephalalgia* 2019; 39: 1075–1085.
 103. Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2023; 402: 775–785.
 104. Yurekli VA, Akhan G, Kutluhan S, et al. The effect of sodium valproate on chronic daily headache and its subgroups. *J Headache Pain* 2008; 9: 37–41.
 105. Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. *Clin Neuropharmacol* 2005; 28: 277–279.
 106. Chowdhury D, Bansal L, Duggal A, et al. TOP-PRO study: a randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. *Cephalalgia* 2022; 42: 396–408.
 107. Deligianni CI, Sacco S, Ekizoglu E, et al. European headache federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 2: flunarizine. *J Headache Pain* 2023; 24: 128.
 108. Lee MJ, Al-Karaghali MA-M and Reuter U. New migraine prophylactic drugs: current evidence and practical suggestions for non-responders to prior therapy. *Cephalalgia* 2023; 43: 03331024221146315.
 109. Overeem LH, Peikert A, Hofacker MD, et al. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. *Cephalalgia* 2022; 42: 291–301.
 110. Patier Ruiz I, Sanchez-Rubio Ferrandez J, Carcamo Fonfria A, et al. Early experiences in switching between monoclonal antibodies in patients with nonresponsive migraine in Spain: a case series. *Eur Neurol* 2022; 85: 132–135.
 111. Diener H-C, Förderreuther S, Gaul C, et al. Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor. *Neurological Res Prac* 2020; 2: 11.
 112. Pellesi L, Do TP, Ashina H, et al. Dual therapy with anti-CGRP monoclonal antibodies and Botulinum toxin for migraine prevention: is there a rationale? *Headache* 2020; 60: 1056–1065.
 113. Scuteri D, Tonin P, Nicotera P, et al. Pooled analysis of real-world evidence supports anti-CGRP mAbs and onabotulinumtoxin combined trial in chronic migraine. *Toxins* 2022; 14: 529.
 114. Hoffmann J, Mehnert J, Koo EM, et al. Greater occipital nerve block modulates nociceptive signals within the trigeminocervical complex. *J Neurol Neurosurg Psychiatr* 2021; 92: 1335–1340.
 115. Chowdhury D, Munda A, Datta D, et al. Efficacy and tolerability of combination treatment of topiramate and greater occipital nerve block versus topiramate monotherapy for the preventive treatment of chronic migraine: a randomized controlled trial. *Cephalalgia* 2022; 42: 859–871.
 116. Chowdhury D, Tomar A, Deorari V, et al. Greater occipital nerve blockade for the preventive treatment of chronic migraine: a randomized double-blind placebo-controlled study. *Cephalalgia* 2023; 43: 03331024221143541.
 117. Dilli E, Halker R, Vargas B, et al. Occipital nerve block for the short-term preventive treatment of migraine: a randomized, double-blinded, placebo-controlled study. *Cephalalgia* 2015; 35: 959–968.
 118. Gul HL, Ozon AO, Karadas O, et al. The efficacy of greater occipital nerve blockade in chronic migraine: a placebo-controlled study. *Acta Neurol Scand* 2017; 136: 138–144.
 119. Ozer D, Boluk C, Turk Boru U, et al. Greater occipital and supraorbital nerve blockade for the preventive treatment of migraine: a single-blind, randomized, placebo-controlled study. *Curr Med Res Opin* 2019; 35: 909–915.
 120. Palamar D, Uluduz D, Saip S, et al. Ultrasound-guided greater occipital nerve block: an efficient technique in chronic refractory migraine without aura? *Pain Physician* 2015; 18: 153–162.
 121. Velasquez-Rimachi V, Chachaima-Mar J, Cardenas-Baltazar EC, et al. Greater occipital nerve block for chronic migraine patients: a meta-analysis. *Acta Neurol Scand* 2022; 146: 101–114.
 122. Malekian N, Bastani PB, Oveisgharan S, et al. Preventive effect of greater occipital nerve block on patients with episodic migraine: a randomized double-blind placebo-controlled clinical trial. *Cephalalgia* 2022; 42: 481–489.
 123. Abu-Arafeh I, Razak S, Sivaraman B, et al. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. *Dev Med Child Neurol* 2010; 52: 1088–1097.
 124. Barnes NP. Migraine headache in children. *BMJ Clin Evid* 2015; Jun 5 0318.
 125. Arruda MA and Bigal ME. Migraine and migraine subtypes in preadolescent children: association with school performance. *Neurology* 2012; 79: 1881–1888.
 126. Powers SW, Coffey CS, Chamberlin LA, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. *N Engl J Med* 2017; 376: 115–124.
 127. Stubberud A, Flaaen NM, McCrory DC, et al. Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. *Pain* 2019; 160: 762–772.
 128. Lewis D, Winner P, Saper J, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. *Pediatrics* 2009; 123: 924–934.
 129. Lakshmi CV, Singhi P, Malhi P, et al. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. *J Child Neurol* 2007; 22: 829–835.
 130. Winner P, Gendolla A, Stayer C, et al. Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety. *Headache* 2006; 46: 1503–1510.
 131. Le K, Yu D, Wang J, et al. Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials. *J Headache Pain* 2017; 18: 69.
 132. Hershey AD, Powers SW, Benti AL, et al. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. *Headache* 2000; 40: 539–549.
 133. Locher C, Kossowsky J, Koechlin H, et al. Efficacy, safety, and acceptability of pharmacologic treatments for pediatric

- migraine prophylaxis: a systematic review and network meta-analysis. *JAMA Pediatr* 2020; 174: 341–349.
134. Kvisvik EV, Stovner LJ, Helde G, et al. Headache and migraine during pregnancy and puerperium: the MIGRA-study. *J Headache Pain* 2011; 12: 443–451.
 135. MacGregor EA. Migraine in pregnancy and lactation. *Neurol Sci* 2014; 35: 61–64.
 136. Melhado EM, Maciel JA Jr. and Guerreiro CA. Headache during gestation: evaluation of 1101 women. *Can J Neurol Sci* 2007; 34: 187–192.
 137. Goadsby PJ, Goldberg J and Silberstein SD. Migraine in pregnancy. *BMJ* 2008; 336: 1502–1504.
 138. Martin PR. Behavioral management of migraine headache triggers: learning to cope with triggers. *Curr Pain Headache Rep* 2010; 14: 221–227.
 139. Göbel H. Non pharmaceutical treatments for migraine. *Rev Neurol (Paris)* 2005; 161: 685–686.
 140. Graves BW. Management of migraine headaches. *J Midwifery Womens Health* 2006; 51: 174–184.
 141. Fox AW, Diamond ML and Spierings EL. Migraine during pregnancy: options for therapy. *CNS Drugs* 2005; 19: 465–481.
 142. Chan CWH, Au Yeung E and Law BMH. Effectiveness of physical activity interventions on pregnancy-related outcomes among pregnant women: a systematic review. *Int J Environ Res Public Health* 2019; 16: 1840.
 143. Pérez-Muñoz A, Buse DC and Andrasik F. Behavioral interventions for migraine. *Neurol Clin* 2019; 37: 789–813.
 144. Puledda F and Shields K. Non-Pharmacological approaches for migraine. *Neurotherapeutics* 2018; 15: 336–345.
 145. Patel PS and Minen MT. Complementary and integrative health treatments for migraine. *J Neuroophthalmol* 2019; 39: 360–369.
 146. Brandes JL. Migraine in women. *Continuum (Minneap Minn)* 2012; 18: 835–852.
 147. Penzien DB, Rains JC and Andrasik F. Behavioral management of recurrent headache: three decades of experience and empiricism. *App Psychophysiol Biofeedback* 2002; 27: 163–181.
 148. Moisset X, Pereira B, Ciampi de Andrade D, et al. Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials. *J Headache Pain* 2020; 21: 142.
 149. Digre KB. What's new in the treatment of migraine? *J Neuroophthalmol* 2019; 39: 352–359.
 150. Tao H, Wang T, Dong X, et al. Effectiveness of transcutaneous electrical nerve stimulation for the treatment of migraine: a meta-analysis of randomized controlled trials. *J Headache Pain* 2018; 19: 42.
 151. Evers S. Non-Invasive Neurostimulation Methods for Acute and Preventive Migraine Treatment-A Narrative Review. *J Clin Med* 2021; 10: 3302.
 152. Puledda F and Goadsby PJ. An update on non-pharmacological neuromodulation for the acute and preventive treatment of migraine. *Headache* 2017; 57: 685–691.
 153. Judkins A, Johnson RL, Murray ST, et al. Vagus nerve stimulation in pregnant rats and effects on inflammatory markers in the brainstem of neonates. *Pediatr Res* 2018; 83: 514–519.
 154. Ahlbom A, Bridges J, de Seze R, et al. Possible effects of electromagnetic fields (EMF) on human health—opinion of the scientific committee on emerging and newly identified health risks (SCENIHR). *Toxicology* 2008; 246: 248–250.
 155. Mauskop A. Nonmedication, alternative, and complementary treatments for migraine. *Continuum (Minneap Minn)* 2012; 18: 796–806.
 156. Lai TH and Huang TC. Update in migraine preventive treatment. *Prog Brain Res* 2020; 255: 1–27.
 157. Silberstein SD. Migraine: preventive treatment. *Curr Med Res Opin* 2001; 17: s87–s93.
 158. Contag SA and Bushnell C. Contemporary management of migrainous disorders in pregnancy. *Curr Opin Obstet Gynecol* 2010; 22: 437–445.
 159. Amundsen S, Nordeng H, Nezvalová-Henriksen K, et al. Pharmacological treatment of migraine during pregnancy and breastfeeding. *Nat Rev Neurol* 2015; 11: 209–219.
 160. Wells RE, Turner DP, Lee M, et al. Managing migraine during pregnancy and lactation. *Curr Neurol Neurosci Rep* 2016; 16: 40.
 161. Habib A and McCarthy JS. Effects on the neonate of propranolol administered during pregnancy. *J Pediatrics* 1977; 91: 808–811.
 162. Tepper D. Pregnancy and lactation—migraine management. *Headache* 2015; 55: 607–608.
 163. Shahien R and Beiruti K. Preventive agents for migraine: focus on the antiepileptic drugs. *J Cent Nerv Syst Dis* 2012; 4: 37–49.
 164. Marmura MJ. Safety of topiramate for treating migraines. *Expert Opin Drug Saf* 2014; 13: 1241–1247.
 165. Hutchinson S, Marmura MJ, Calhoun A, et al. Use of common migraine treatments in breast-feeding women: a summary of recommendations. *Headache* 2013; 53: 614–627.
 166. Davanzo R, Bua J, Paloni G, et al. Breastfeeding and migraine drugs. *Eur J Clin Pharmacol* 2014; 70: 1313–1324.
 167. Bethesda (MD): *National Institute of Child Health and Human Development. Drugs and Lactation Database (LactMed®)*. 2006. <https://www.ncbi.nlm.nih.gov/books/NBK501922/> (accessed 21 August 2024).
 168. Chen H, Jin Z, Xia F, et al. Bupivacaine inhibits a small conductance calcium-activated potassium type 2 channel in human embryonic kidney 293 cells. *BMC Pharmacol Toxicol* 2021; 22: 15.
 169. Wijeratne T, Tang HM, Crewther D, et al. Prevalence of migraine in the elderly: a narrated review. *Neuroepidemiology* 2019; 52: 104–110.
 170. Soni PP, Lee M, Shadbeh N, et al. Recent advances in the management of migraine in older patients. *Drugs Aging* 2020; 37: 463–468.
 171. Curto M, Capi M, Martelletti P, et al. How do you choose the appropriate migraine pharmacotherapy for an elderly person? *Expert Opin Pharmacother* 2019; 20: 1–3.
 172. Riggins N and Ehrlich A. Episodic migraine and older adults. *Curr Pain Headache Rep* 2022; 26: 331–335.
 173. Caponnetto V, Deodato M, Robotti M, et al. Comorbidities of primary headache disorders: a literature review with meta-analysis. *J Headache Pain* 2021; 22: 71.
 174. Sarchielli P, Mancini ML and Calabresi P. Practical considerations for the treatment of elderly patients with migraine. *Drugs Aging* 2006; 23: 461–489.

175. Landy SH and Lobo BL. Migraine treatment throughout the lifecycle. *Expert Rev Neurother* 2005; 5: 343–353.
176. David DJ and Gourion D. Antidepressant and tolerance: determinants and management of major side effects. *Encephale* 2016; 42: 553–561.
177. Mathew S and Ailani J. Traditional and novel migraine therapy in the aging population. *Curr Pain Headache Rep* 2019; 23: 42.
178. Banzi R, Cusi C, Randazzo C, et al. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults. *Cochrane Database Syst Rev* 2015; 2015: CD011681.
179. Kirby D, Harrigan S and Ames D. Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. *Int J Geriatr Psychiatry* 2002; 17: 231–237.
180. Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. *Clin Neurol Neurosurg* 2004; 107: 44–48.
181. Berk T, Ashina S, Martin V, et al. Diagnosis and treatment of primary headache disorders in older adults. *J Am Geriatr Soc* 2018; 66: 2408–2416.
182. Dorosch T, Ganzer CA, Lin M, et al. Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults. *Curr Pain Headache Rep* 2019; 23: 85.
183. Hu C, Zhang Y and Tan G. Advances in topiramate as prophylactic treatment for migraine. *Brain Behav* 2021; 11: e2290.
184. Brodie MJ and Kwan P. Epilepsy in elderly people. *BMJ* 2005; 331: 1317–1322.
185. Karsan N, Palethorpe D, Rattanawong W, et al. Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK. *Eur J Neurol* 2018; 25: 811–817.
186. Martinelli D, Arceri S, Tronconi L, et al. Chronic migraine and Botulinum toxin type A: where do paths cross? *Toxicon* 2020; 178: 69–76.
187. Altamura C, Ornello R, Ahmed F, et al. Onabotulinumtoxin A in elderly patients with chronic migraine: insights from a real-life European multicenter study. *J Neurol* 2023; 270: 986–994.
188. Diener HC, McAllister P, Jürgens TP, et al. Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. *Cephalalgia* 2022; 42: 769–780.
189. Muñoz-Vendrell A, Campoy S, Caronna E, et al. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients. *J Headache Pain* 2023; 24: 63.
190. Stauffer VL, Turner I, Kemmer P, et al. Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials. *J Headache Pain* 2020; 21: 79.
191. Reuter U, Lucas C, Dolezil D, et al. Galcanezumab in patients with multiple previous migraine preventive medication category failures: results from the open-label period of the CONQUER trial. *Adv Ther* 2021; 38: 5465–5483.
192. Lampl C, Kraus V, Lehner K, et al. Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials. *J Headache Pain* 2022; 23: 104.
193. Rissardo JP and Caprara ALF. Gepants for acute and preventive migraine treatment: A narrative review. *Brain Sci* 2022; 12: 1612.
194. Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. *New England Journal of Medicine* 2021; 385: 695–706.
195. Tassorelli C, Nagy K, Pozo-Rosich P, et al. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. *Lancet Neurol* 2024; 23: 382–392.
196. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. *Lancet* 2019; 394: 737–745.
197. Schwedt TJ, Myers Oakes TM, Martinez JM, et al. Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: results from a randomized, controlled clinical trial. *Neurol Ther* 2024; 13: 85–105.
198. Ivans A, Stringfellow J, Coric V, et al. Rimegepant 75 mg exposure, safety, and tolerability are similar in elderly and nonelderly adults: a phase 1, open-label, parallel-group, single-dose study (2101). *Neurology* 2020; 94: 2101.
199. Hugger SS, Do TP, Ashina H, et al. Migraine in older adults. *Lancet Neurol* 2023; 22: 934–945.
200. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. *Cephalalgia* 2018; 38: 1–211.
201. Ashina S, Terwindt GM, Steiner TJ, et al. Medication overuse headache. *Nat Rev Dis Primers* 2023; 9: 5.
202. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the global burden of disease study 2013. *Lancet* 2015; 386: 743–800.
203. Tassorelli C, Jensen R, Allena M, et al. A consensus protocol for the management of medication-overuse headache: evaluation in a multicentric, multinational study. *Cephalalgia* 2014; 34: 645–655.
204. Westergaard ML, Glumer C, Hansen EH, et al. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. *Pain* 2014; 155: 2005–2013.
205. Diener HC, Antonaci F, Braschinsky M, et al. European academy of neurology guideline on the management of medication-overuse headache. *Eur J Neurol* 2020; 27: 1102–1116.
206. Rossi P, Di Lorenzo C, Faroni J, et al. Advice alone vs. Structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. *Cephalalgia* 2006; 26: 1097–1105.
207. Zeeberg P, Olesen J and Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. *Neurology* 2006; 66: 1894–1898.

208. Carlsen LN, Munksgaard SB, Jensen RH, et al. Complete detoxification is the most effective treatment of medication-overuse headache: a randomized controlled open-label trial. *Cephalalgia* 2018; 38: 225–236.
209. Carlsen LN, Munksgaard SB, Nielsen M, et al. Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. *JAMA Neurol* 2020; 77: 1069–1078.
210. Sarchielli P, Messina P, Cupini LM, et al. Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial. *Eur Neuropsychopharmacol* 2014; 24: 1289–1297.
211. Silberstein SD, Blumenfeld AM, Cady RK, et al. Onabotulinumtoxin A for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. *J Neurol Sci* 2013; 331: 48–56.
212. Pijpers JA, Kies DA, Louter MA, et al. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial. *Brain* 2019; 142: 1203–1214.
213. Schwedt TJ, Hentz JG, Sahai-Srivastava S, et al. Patient-Centered treatment of chronic migraine with medication overuse: a prospective, randomized, pragmatic clinical trial. *Neurology* 2022; 98: e1409–e1421.
214. Dodick DW, Doty EG, Aurora SK, et al. Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. *Cephalalgia* 2021; 41: 340–352.
215. Silberstein SD, Cohen JM, Seminerio MJ, et al. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. *J Headache Pain* 2020; 21: 114.
216. Diener HC, Marmura MJ, Tepper SJ, et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. *Headache* 2021; 61: 125–136.
217. Lipton RB, Serrano D, Nicholson RA, et al. Impact of NSAID and triptan use on developing chronic migraine: results from the American migraine prevalence and prevention (AMPP) study. *Headache* 2013; 53: 1548–1563.